10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)                                                                                                               
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2008
or
[   ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________.

Commission File Number 1-8269

OMNICARE, INC.
(Exact name of registrant as specified in its charter)

Delaware	31-1001351
(State or other jurisdiction of	(I.R.S. Employer Identification No.)
incorporation or organization)

	100 East RiverCenter Boulevard, Covington, Kentucky 41011
	(Address of principal executive offices)                  (Zip Code)
(859) 392-3300
(Registrant’s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant:

	1)	has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and
	2)	has been subject to such filing requirements for the past 90 days.
			Yes [ x ] No [   ]
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[ x ]	Accelerated filer	[    ]
Non-accelerated filer	[    ] (Do not check if a smaller reporting company)	Smaller reporting company	[    ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [   ] No [ x ]

COMMON STOCK OUTSTANDING
	Number of
	Shares	Date
Common Stock, $1 par value	121,617,458	March 31, 2008

OMNICARE, INC. AND
SUBSIDIARY COMPANIES
FORM 10-Q QUARTERLY REPORT MARCH 31, 2008
INDEX
		PAGE
PART I - FINANCIAL INFORMATION:
ITEM 1.	FINANCIAL STATEMENTS (UNAUDITED)
	Consolidated Statements of Income –
	Three months ended – March 31, 2008 and 2007	3
	Consolidated Balance Sheets –
	March 31, 2008 and December 31, 2007	4
	Consolidated Statements of Cash Flows –
	Three months ended – March 31, 2008 and 2007	5
	Notes to Consolidated Financial Statements	6
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF
	FINANCIAL CONDITION AND RESULTS OF OPERATIONS	34
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
	MARKET RISK	57
ITEM 4.	CONTROLS AND PROCEDURES	59
PART II - OTHER INFORMATION:
ITEM 1.	LEGAL PROCEEDINGS	59
ITEM 1A.	RISK FACTORS	62
ITEM 2.	UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF
	PROCEEDS	69
ITEM 6.	EXHIBITS	69

PART I - FINANCIAL INFORMATION:
ITEM 1. - FINANCIAL STATEMENTS
CONSOLIDATED STATEMENTS OF INCOME
OMNICARE, INC. AND SUBSIDIARY COMPANIES
UNAUDITED
(in thousands, except per share data)
	Three months ended, March 31,
	2008			2007
Net sales	$	1,558,979		$	1,577,065
Cost of sales		1,177,763			1,190,993
Heartland matters (Note 10)		1,574			4,296
Gross profit		379,642			381,776
Selling, general and administrative
expenses		236,597			225,609
Provision for doubtful accounts		30,392			28,904
Restructuring and other related
charges (Note 9)		6,448			9,174
Litigation and other related professional fees (Note 10)		21,642			6,907
Heartland matters (Note 10)		319			1,496
Operating income		84,244			109,686
Investment income		2,611			1,921
Interest expense		(37,056	)		(42,048	)
Income before income taxes		49,799			69,559
Income tax provision		19,855			26,572
Net income	$	29,944		$	42,987
Earnings per share:
Basic	$	0.25		$	0.36
Diluted	$	0.25		$	0.35
Dividends per common share	$	0.0225		$	0.0225
Weighted average number of common
shares outstanding:
Basic		119,848		$	119,077
Diluted		120,538		$	121,378
Comprehensive income	$	39,071		$	45,375
The Notes to Consolidated Financial Statements are an integral part of these statements.

3

CONSOLIDATED BALANCE SHEETS OMNICARE, INC. AND SUBSIDIARY COMPANIES (in thousands, except share data)
	(UNAUDITED)
	March 31,			December 31,
	2008			2007
ASSETS
Current assets:
Cash and cash equivalents	$	301,260		$	274,448
Restricted cash		14,764			3,155
Accounts receivable, less allowances of $348,588 (2007-$334,061)		1,357,736			1,376,288
Unbilled receivables, CRO		29,740			24,855
Inventories		409,098			448,183
Deferred income tax benefits		133,514			126,239
Other current assets		209,638			202,982
Total current assets		2,455,750			2,456,150
Properties and equipment, at cost less accumulated depreciation of      $321,306 (2007-$311,422)		199,886			199,449
Goodwill		4,346,959			4,342,169
Identifiable intangible assets, less accumulated amortization of      $123,696 (2007-$115,042)		317,929			323,637
Rabbi trust assets for settlement of pension obligations		122,957			123,035
Other noncurrent assets		130,611			149,339
Total noncurrent assets		5,118,342			5,137,629
Total assets	$	7,574,092		$	7,593,779
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	330,107		$	371,020
Accrued employee compensation		46,799			32,696
Deferred revenue, CRO		18,779			22,068
Current debt		2,848			3,192
Other current liabilities		234,607			223,184
Total current liabilities		633,140			652,160
Long-term debt, notes and convertible debentures		2,776,099			2,820,751
Deferred income tax liabilities		483,494			449,789
Other noncurrent liabilities		351,356			379,376
Total noncurrent liabilities		3,610,949			3,649,916
Total liabilities		4,244,089			4,302,076
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, no par value, 1,000,000 shares authorized, none
issued and outstanding		-			-
Common stock, $1 par value, 200,000,000 shares authorized,           124,601,900 shares issued (2007-124,599,300 shares issued)		124,602			124,599
Paid-in capital		1,921,825			1,917,062
Retained earnings		1,425,029			1,397,831
Treasury stock, at cost-2,984,400 shares (2007-2,827,300 shares)		(92,582	)		(89,791	)
Accumulated other comprehensive income		(48,871	)		(57,998	)
Total stockholders' equity		3,330,003			3,291,703
Total liabilities and stockholders' equity	$	7,574,092		$	7,593,779

The Notes to Consolidated Financial Statements are an integral part of these statements.

4

CONSOLIDATED STATEMENTS OF CASH FLOWS OMNICARE, INC. AND SUBSIDIARY COMPANIES UNAUDITED (in thousands)
	Three months ended March 31,
	2008			2007
Cash flows from operating activities:
Net income	$	29,944		$	42,987
Adjustments to reconcile net income to net cash flows from      operating activities:
Depreciation		12,933			14,190
Amortization		16,582			14,532
Provision for doubtful accounts		30,392			28,904
Deferred tax provision		23,977			13,257
Changes in assets and liabilities, net of effects from acquisition      of businesses:
Accounts receivable and unbilled receivables		(14,990	)		(26,663	)
Inventories		39,966			(19,322	)
Deposits with drug wholesalers		-			(486	)
Other current and noncurrent assets		23,415			(6,323	)
Accounts payable		(43,626	)		72,585
Accrued employee compensation		14,109			11,497
Deferred revenue		(3,289	)		(934	)
Current and noncurrent liabilities		12,851			30,565
Net cash flows from operating activities		142,264			174,789
Cash flows from investing activities:
Acquisition of businesses, net of cash received		(35,983	)		(43,305	)
Capital expenditures		(12,439	)		(8,281	)
Transfer of cash to trusts for employee health and severance           costs, net of payments out of the trust		(11,542	)		(10,322	)
Other		(32	)		(24	)
Net cash flows used by investing activities		(59,996	)		(61,932	)
Cash flows from financing activities:
Borrowings on line of credit facilities and term A loan		49,000			74,000
Payments on line of credit facilities and term A loan		(99,000	)		(124,000	)
Payments on long-term borrowings and obligations		(963	)		(1,304	)
Change in cash overdraft balance		(857	)		(7,986	)
Payments for stock awards and exercise of stock options,           net of stock tendered in payment		(3,584	)		(8,232	)
Excess tax benefits from stock-based compensation		82			4,063
Dividends paid		(2,746	)		(2,739	)
Net cash flows used in financing activities		(58,068	)		(66,198	)
Effect of exchange rate changes on cash		2,612			553
Net increase in cash and cash equivalents		26,812			47,212
Cash and cash equivalents at beginning of period		274,448			138,034
Cash and cash equivalents at end of period	$	301,260		$	185,246

The Notes to Consolidated Financial Statements are an integral part of these statements.

5

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
OMNICARE, INC. AND SUBSIDIARY COMPANIES
UNAUDITED

Note 1 - Interim Financial Data, Description of Business and Summary of Significant Accounting Policies

Interim Financial Data

The interim financial data is unaudited; however, in the opinion of the management of Omnicare, Inc., the interim data includes all adjustments (which include only normal adjustments, except as described in the “Restructuring and Other Related Charges” and “Commitments and Contingencies” notes) considered necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of Omnicare, Inc. and its consolidated subsidiaries (“Omnicare” or the “Company”). These financial statements should be read in conjunction with the Consolidated Financial Statements and related notes included in Omnicare’s Annual Report on Form 10-K for the year ended December 31, 2007 (“Omnicare’s 2007 Annual Report”) and any related updates included in the Company’s periodic quarterly Securities and Exchange Commission (“SEC”) filings. Certain reclassifications of prior year amounts have been made to conform with the current year presentation.

Description of Business and Summary of Significant Accounting Policies

The Company’s description of business and significant accounting policies have been disclosed in Omnicare’s 2007 Annual Report. As previously disclosed, these financial statements should be read in conjunction with the Consolidated Financial Statements and related notes included in Omnicare’s 2007 Annual Report and any related updates contained in the Company’s periodic quarterly SEC filings, including those presented below.

Concentration of Credit Risk

The prescription drug benefit under Medicare Part D (“Part D”) became effective on January 1, 2006. As a result, providers of long-term care pharmacy services, including Omnicare, experienced a significant shift in payor mix beginning in 2006. Approximately 41% of the Company’s revenues in the three months ended March 31, 2008 were generated under the Part D program. The Company estimates that approximately 24% of these Part D revenues during the three months ended March 31, 2008 relate to patients enrolled in Part D prescription drug plans sponsored by UnitedHealth Group and its Affiliates (“United”). Prior to the implementation of the Medicare Part D program, most of the Part D residents served by the Company were reimbursed under state Medicaid programs and, to a lesser extent, private pay sources.

Under the Part D benefit, payment is determined in accordance with the agreements Omnicare has negotiated with the Part D Plans. The remainder of Omnicare’s billings are paid or reimbursed primarily by long-term care facilities (including revenues for residents funded under Medicare Part A) and other third party payors, including private insurers, state Medicaid programs, as well as individual residents.

The Medicaid and Medicare programs are highly regulated. The failure, even if inadvertent, of Omnicare and/or client facilities to comply with applicable reimbursement regulations could adversely affect Omnicare’s reimbursement under these programs and Omnicare’s ability to continue to participate in these programs. In addition, failure to comply with these regulations could subject the Company to other penalties.

As noted, the Company obtains reimbursement for drugs it provides to enrollees of a given Part D Plan in accordance with the terms of the agreement negotiated between it and that Part D Plan. The Company has

6

entered into such agreements with nearly all Part D Plan sponsors under which it will provide drugs and associated services to their enrollees. The Company continues to have ongoing discussions with Part D Plans in the ordinary course. The Company may, as appropriate, renegotiate agreements. Moreover, as expected in the transition to a program of this magnitude, certain administrative and payment issues have arisen, resulting in higher operating expenses, as well as outstanding gross accounts receivable (net of allowances for contractual adjustments, and prior to any allowance for doubtful accounts) for copays and rejected claims. As of March 31, 2008, copays outstanding from Part D Plans were approximately $43 million, of which approximately $19 million relates to 2006. Additionally, as of March 31, 2008, Part D rejected claims outstanding from Part D Plans for the 2006 transitional year were approximately $21 million.

On July 11, 2007, the Company commenced legal action against a group of its customers for, among other things, the collection of past-due receivables that are owed to the Company. Specifically, approximately $87 million (excluding interest) is owed to the Company by this group of customers as of March 31, 2008, of which approximately $79 million is past due based on applicable payment terms (a significant portion of which is not reserved).

Until these administrative and payment issues relating to the Part D Drug Benefit as well as the aforementioned legal action against a group of Omnicare’s customers are fully resolved, there can be no assurance that the impact of these matters on the Company’s results of operations, financial position or cash flows will not change based on the outcome of any unforeseen future developments.

Accumulated Other Comprehensive Income (Loss)

The accumulated other comprehensive income (loss) balances at March 31, 2008 and December 31, 2007, net of aggregate applicable tax benefits of $37.9 million and $40.2 million, respectively, by component and in the aggregate, follow (in thousands):

	March 31, 2008			December 31, 2007
Cumulative foreign currency translation adjustments	$	8,268		$	3,888
Unrealized gain on fair value of investments		5,270			2,400
Pension and postemployment benefits		(62,409	)		(64,286	)
Total accumulated other comprehensive loss adjustments, net	$	(48,871	)	$	(57,998	)

Common Stock Repurchase Program

On March 27, 2008, the Company announced that its Board of Directors has authorized a new program to repurchase, from time to time, shares of Omnicare's outstanding common stock having an aggregate value of up to $100 million, depending on market conditions and other factors. On March 31, 2008, Omnicare had approximately 121.6 million shares of common stock outstanding. These repurchases will be made in open market or privately negotiated transactions in compliance with Securities and Exchange Commission Rule 10b-18 and other applicable legal requirements. The manner, timing and amount of any purchases will be determined by the Company based on an evaluation of market conditions, stock price and other factors. The plan does not obligate Omnicare to acquire any particular amount of common stock, and it may be modified or suspended at any time at Omnicare's discretion.

7

Recently Issued Accounting Standards

In December 2007, the Financial Accounting Standards Board (“FASB”) issued Statement of Financial Accounting Standards (“SFAS”) No. 141 (revised 2007), “Business Combinations” (“SFAS 141R”). Among other changes, SFAS 141R requires the acquiring entity in a business combination to recognize all (and only) the assets acquired and liabilities assumed in the transaction at fair value; establishes the acquisition-date fair value as the measurement objective for all assets acquired and liabilities assumed, including earn-out provisions. SFAS 141R is generally effective for business combinations occurring in the first annual reporting period beginning after December 15, 2008. The Company is evaluating the anticipated effect of this recently issued standard on its future consolidated results of operations, financial position and cash flows.

In December 2007, the FASB issued SFAS No. 160, “Noncontrolling Interests in Consolidated Financial Statements, an amendment of ARB No. 51” (“SFAS 160”). Among other items, SFAS 160 requires all entities to report noncontrolling (minority) interests in subsidiaries in the same way as equity in the consolidated financial statements. SFAS 160 is effective for the first annual reporting period beginning after December 15, 2008. The Company is evaluating the anticipated effect of this recently issued standard on its consolidated results of operations, financial position and cash flows.

In December 2007, the FASB issued SFAS No. 161, “Disclosures about Derivative Instruments and Hedging Activities, an amendment of FASB Statement No. 133” (“SFAS 161”). Among other items, SFAS 161 requires qualitative disclosures about objectives and strategies for using derivatives, quantitative disclosures about fair value amounts of, and gains and losses on, derivative instruments, and disclosures about credit-risk-related contingent features in derivative agreements. SFAS 161 is effective for the first annual reporting period beginning after November 15, 2008. The Company is evaluating the anticipated effect of this recently issued standard on its consolidated results of operations, financial position and cash flows.

Note 2 - Acquisitions

Since 1989, the Company has been involved in a program to acquire providers of pharmaceutical products and related pharmacy services to long-term care facilities and their residents as well as patients in other care settings. The Company’s strategy has included the acquisition of freestanding institutional pharmacy businesses as well as other assets, generally insignificant in size, which have been combined with existing pharmacy operations to augment their internal growth. From time-to-time the Company may acquire other businesses, such as pharmacy consulting companies, specialty pharmacy companies, medical supply and service companies, hospice pharmacy companies and companies providing distribution and product support services for specialty pharmaceuticals, as well as contract research organizations, which complement the Company’s core businesses.

During the first three months of 2008, Omnicare completed three acquisitions of businesses in the Pharmacy Services segment, none of which were, individually or in the aggregate, significant to the Company. Acquisitions of businesses required outlays of $36.0 million (including amounts payable pursuant to acquisition agreements relating to pre-2008 acquisitions) in the three months ended March 31, 2008. The impact of these aggregate acquisitions on the Company’s overall goodwill balance has been reflected in the disclosures at the “Goodwill and Other Intangible Assets” note. The Company continues to evaluate the tax effects, identifiable intangible assets and other pre-acquisition contingencies relating to certain acquisitions. Omnicare is in the process of completing its allocation of the purchase price for certain acquisitions and, accordingly, the goodwill and other identifiable intangible assets balances are preliminary and subject to change. The net assets and operating results of acquisitions have been included in the Company’s consolidated financial statements from their respective dates of acquisition.

8

Note 3 - Goodwill and Other Intangible Assets

Changes in the carrying amount of goodwill for the three months ended March 31, 2008, by business segment, are as follows (in thousands):

	Pharmacy			CRO
	Services			Services		Total
Balance as of December 31, 2007	$	4,250,114		$	92,055	$	4,342,169
Goodwill acquired in the three months      ended March 31, 2008		10,334			-		10,334
Other		(6,301	)		757		(5,544	)
Balance as of March 31, 2008	$	4,254,147		$	92,812	$	4,346,959

The “Other” caption above includes the settlement of acquisition matters relating to prior-year acquisitions (including, where applicable, payments pursuant to acquisition agreements such as deferred payments, indemnification payments and payments originating from earnout provisions, as well as adjustments for the finalization of purchase price allocations, including identifiable intangible asset determinations). “Other” also includes the effect of adjustments due to foreign currency translations, which relate solely to the Contract Research Organization (“CRO”) Services segment and one pharmacy located in Canada that is included in the Pharmacy Services segment.

The decrease in the net carrying amount of the Company’s other identifiable intangible assets of approximately $5.7 million from December 31, 2007, primarily relates to amortization expense recorded during the period, partially offset by increases due primarily to customer relationship assets and non-compete agreements related primarily to recent acquisitions, with a weighted-average life of approximately 11 years.

9

Note 4 - Debt

A summary of debt follows (in thousands):

	March 31, 2008			December 31, 2007
Revolving loans, due 2010	$	-		$	-
Term loan, due 2010		48,915			50,602
Senior term A loan, due 2010		400,000			450,000
6.125% senior subordinated notes, due 2013		250,000			250,000
6.75% senior subordinated notes, due 2013		225,000			225,000
6.875% senior subordinated notes, due 2015		525,000			525,000
4.00% junior subordinated convertible debentures, due 2033		345,000			345,000
3.25% convertible senior debentures, due 2035		977,500			977,500
Capitalized lease and other debt obligations		7,143			8,831
Subtotal		2,778,558			2,831,933
Add/(subtract) interest rate swap agreement		389			(7,990	)
(Subtract) current portion of debt		(2,848	)		(3,192	)
Total long-term debt, net	$	2,776,099		$	2,820,751

The Company’s debt instruments, including related terms and certain financial covenants, have been disclosed in further detail at the “Debt” note of the Notes to Consolidated Financial Statements in Omnicare’s 2007 Annual Report.

At March 31, 2008, there was no outstanding balance under the Company’s $800 million revolving credit facility, maturing on July 28, 2010 (“Revolving Loans”), and $400 million outstanding under the Company’s senior term A loan facility, maturing on July 28, 2010 (the “Term Loans”). The Company repaid $50 million on the Term Loans during the three months ended March 31, 2008. The interest rate on the Term Loans was 3.95% at March 31, 2008. As of March 31, 2008, the Company had approximately $26.6 million outstanding relating to standby letters of credit, substantially all of which are subject to automatic annual renewals. The Company amortized to expense $2.0 million of deferred debt issuance costs during the three months ended March 31, 2008 and 2007.

At March 31, 2008, the overall weighted-average interest rate on the Company’s variable interest portion of its long-term debt, excluding the interest rate swap agreement, was 4.28%. The estimated floating interest rate on the interest rate swap agreement was 4.90% at March 31, 2008.

Note 5 - Fair Value

On January 1, 2008, the Company partially adopted the provisions of SFAS No. 157, “Fair Value Measurements” (“SFAS 157”). SFAS 157 defines a hierarchy which prioritizes the inputs in fair value measurements. “Level 1” measurements are measurements using quoted prices in active markets for identical assets or liabilities. “Level 2” measurements use significant other observable inputs. “Level 3” measurements are measurements using significant unobservable inputs which require a company to develop its own assumptions. In recording the fair value of assets and liabilities, companies must use the most reliable measurement available. The impact to the Company’s consolidated results of operations, financial position and

10

cash flows upon partial adoption of SFAS 157 was not material. The Company elected to partially defer adoption of SFAS 157 related to goodwill and indefinite-lived intangible assets in accordance with FASB Staff Position 157-2.

			Based on
	Fair Value at March 31, 2008		Quoted Prices in Active Markets (Level 1)		Other Observable Inputs (Level 2)		Unobservable Inputs (Level 3)
Assets and (Liabilities) Measured at Fair Value on a Recurring Basis:(1)
Rabbi trust assets (2)	$	122,957	$	122,957	$	-	$	-
Interest rate swap agreement - fair value hedge (3)		389		-		389		-
Derivatives (4)		-		-		-		-
Total	$	123,346	$	122,957	$	389	$	-

(1)	For cash and cash equivalents, restricted cash, accounts receivable, unbilled receivables, and accounts payable, the net carrying value of these items approximates their fair value at quarter end. Further, at March 31, 2008, the fair value of Omnicare’s variable rate debt facilities approximates the carrying value, as the effective interest rates fluctuate with changes in market rates. The fair value of the Company’s fixed-rate debt facilities is based on quoted market prices and, while not recorded on the Consolidated Balance Sheets and thus excluded from the fair value table above, these fair values are summarized at the “Quantitative and Qualitative Disclosures About Market Risk” section at Part I, Item 3 of this Filing.
(2)	The fair value of restricted funds held in trust (rabbi trust assets) for settlement of the Company’s employee benefit obligations is based on quoted market prices of the investments held by the trustee.
(3)	In connection with its offering of $250 million of 6.125% senior subordinated notes due 2013 (the “6.125% Senior Notes”), the Company entered into an interest rate swap agreement (the “Swap Agreement”) with respect to all $250 million of the aggregate principal amount of the 6.125% Senior Notes. The Swap Agreement hedges against exposure to long-term U.S. dollar interest rates, and is designated and accounted for as a fair value hedge. The Company is accounting for the Swap Agreement in accordance with SFAS No. 133, “Accounting for Derivative Instruments and Hedging Activities,” as amended, so changes in the fair value of the Swap Agreement are offset by changes in the recorded carrying value of the related 6.125% Senior Notes. The fair value of the Swap Agreement is recorded in the “Other noncurrent assets” or “Other noncurrent liabilities” line of the Consolidated Balance Sheets, as applicable, and as an adjustment to the book carrying value of the related 6.125% Senior Notes. The fair value of over-the-counter derivative instruments, such as the Company’s interest rate swap, can be modeled for valuation using a variety of techniques. The Company’s interest rate swap is valued using market inputs with mid-market pricing as a practical expedient for the bid/ask spread as allowed by SFAS 157. As such, the swap is categorized within Level 2 of the hierarchy.
(4)	Embedded in the Company’s 4.00% Trust Preferred Income Equity Redeemable Securities due 2033 (the “Old Trust PIERS”), Series B 4.00% Trust Preferred Income Equity Redeemable Securities due 2033 (the “New Trust PIERS”), and the 3.25% convertible senior debentures due 2035 (the “3.25% Convertible Debentures”) are two derivative instruments, specifically, a contingent interest provision and a contingent conversion parity provision. In addition, the 3.25% Convertible Debentures include an interest reset provision. The embedded derivatives are periodically valued, and at period end, the values of the derivatives embedded in the Old Trust PIERS, the New Trust PIERS and the 3.25% Convertible Debentures were not material. However, the values are subject to change, based on

11

market conditions, which could affect the Company’s consolidated future results of operations, financial position or cash flows and fair value disclosures.

Note 6 - Stock-Based Compensation

At March 31, 2008, the Company had four stock-based employee compensation plans under which incentive awards were outstanding, which are described in further detail at the “Stock-Based Compensation” note of the Notes to Consolidated Financial Statements in Omnicare’s 2007 Annual Report. Omnicare believes that the incentive awards issued under these plans serve to better align the interests of its employees with those of its stockholders. As further described in Omnicare’s 2007 Annual Report, non-vested stock awards are granted to key employees at the discretion of the Compensation and Incentive Committee of the Board of Directors.

Total pretax stock-based compensation expense recognized in the Consolidated Statement of Income as part of S,G&A expense for stock options and stock awards for the three months ended March 31, 2008 and 2007 is as follows (in thousands):

	Three months ended, March 31,
	2008		2007
Stock awards	$	5,695	$	4,447
Stock options		1,031		1,016
Total stock-based compensation      expense	$	6,726	$	5,463

The assumptions used to value stock options granted during the periods ended March 31, 2008 and 2007 are as follows:

	2008			2007
Expected volatility		29.7	%		29.3	%
Risk-free interest rate		2.7	%		4.3	%
Expected dividend yield		0.4	%		0.2	%
Expected term of options (in years)		4.7			4.7
Weighted-average fair value per option	$	6.36		$	13.08

12

A summary of stock option activity under the plans for the three months ended March 31, 2008, is presented below (in thousands, except exercise price and term data):

	Shares		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value
Options outstanding, beginning of period	7,259		$	30.78
Options granted	42			22.64
Options exercised	(2	)		19.83
Options forfeited	(22	)		36.99
Options outstanding, end of period	7,277		$	30.72	4.8	$	4,283
Options exercisable, end of period	6,399		$	29.65	4.3	$	4,283

The total exercise date intrinsic value of options exercised during the three months ended March 31, 2008 was insignificant.

A summary of non-vested restricted stock awards for the three months ended March 31, 2008 is presented below (in thousands, except grant price data):

	Shares		Weighted- Average Grant Date Price
Non-vested shares, beginning of period	2,103		$	37.27
Shares awarded	1			21.80
Shares vested	(483	)		30.28
Shares forfeited	(2	)		42.81
Non-vested shares, end of period	1,619		$	39.35

As of March 31, 2008, there was approximately $64 million of total unrecognized compensation cost related to non-vested stock awards and stock options granted to Omnicare employees, which is expected to be recognized as expense prospectively over a remaining weighted-average period of approximately four years. The total grant date fair value of shares vested during the three months ended March 31, 2008 related to stock awards and stock options was approximately $14.9 million.

Note 7 - Employee Benefit Plans

The Company has various defined contribution savings plans under which eligible employees can participate by contributing a portion of their salary for investment, at the direction of each employee, in one or more investment funds, as further described in Omnicare’s 2007 Annual Report. Expense relating primarily to the Company’s matching contributions for these defined contribution plans was $1.9 million and $1.7 million for the three months ended March 31, 2008 and 2007, respectively.

13

The Company has a non-contributory, defined benefit pension plan covering certain corporate headquarters employees and the employees of several companies sold by the Company in 1992, for which benefits ceased accruing upon the sale (the “Qualified Plan”). Benefits accruing under this plan to corporate headquarters employees were fully vested and frozen as of January 1, 1994.

The Company also has an excess benefit plan (“EBP”) that provides retirement payments to certain headquarters employees in amounts generally consistent with what they would have received under the Qualified Plan. The retirement benefits provided by the EBP are generally comparable to those that would have been earned in the Qualified Plan, if payments under the Qualified Plan were not limited by the Internal Revenue Code.

In addition, the Company has a supplemental pension plan (“SPP”) in which certain of its officers participate. Retirement benefits under the SPP are calculated on the basis of a specified percentage of the officers’ covered compensation, years of credited service and a vesting schedule, as specified in the plan document. All benefits under the SPP became fully vested and accrued as of January 1, 2008. In February of 2008, all participants received a lump sum payment of all their fully accrued benefits under the SPP.

The Qualified Plan is funded with an irrevocable trust, which consists of assets held in the Vanguard Intermediate Term Treasury Fund Admiral Shares fund (“Vanguard Fund”), a mutual fund holding U.S. Treasury obligations. In addition, the Company has established rabbi trusts, which are also held in the Vanguard Fund, to provide for retirement obligations under the EBP. The Company’s general approach is to fund its pension obligations in accordance with the funding provisions of the Employee Retirement Income Security Act.

The following table presents the components of net periodic pension cost for all pension plans for the three months ended March 31, 2008 and 2007 (pretax, in thousands):

	Three months ended March 31,
	2008			2007
Service cost	$	1,499		$	1,087
Interest cost		2,385			2,051
Amortization of deferred amounts      (primarily prior actuarial losses)		3,673			2,901
Return on assets		(54	)		(47	)
Other		(268	)		-
Net periodic pension cost	$	7,235		$	5,992

As of March 31, 2008, the aggregate defined benefit plans’ liabilities total approximately $167 million. During the first three months of 2008, the Company made no payments related to funding the rabbi trusts for the settlement of the Company’s pension obligations, resulting in aggregate assets with a fair value of approximately $123 million at March 31, 2008. The Company currently anticipates making contributions of approximately $1 million during the remainder of the 2008 year.

14

Note 8 - Earnings Per Share Data

Basic earnings per share are computed based on the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share include the dilutive effect of stock options, warrants and restricted stock awards, as well as convertible debentures.

The following is a reconciliation of the numerator and denominator of the basic and diluted earnings per share (“EPS”) computations (in thousands, except per share data):

		Three months ended March 31,
					Per
			Common		Common
		Income	Shares		Share
2008:		(Numerator)	(Denominator)		Amounts
Basic EPS
Net income	$	29,944	119,848	$	0.25
Effect of Dilutive Securities
4.00% junior subordinated convertible      debentures		70	275
Stock options, warrants and awards		-	415
Diluted EPS
Net income plus assumed conversions	$	30,014	120,538	$	0.25
2007:
Basic EPS
Net income	$	42,987	119,077	$	0.36
Effect of Dilutive Securities
4.00% junior subordinated convertible      debentures		72	357
Stock options, warrants and awards		-	1,944
Diluted EPS
Net income plus assumed conversions	$	43,059	121,378	$	0.35

During the three months ended March 31, 2008 and 2007, the anti-dilutive effect associated with certain stock options, warrants and stock awards was excluded from the computation of diluted EPS, since the exercise price was greater than the average market price of the Company’s common stock during these periods. The aggregate number of stock options, warrants and stock awards excluded from the computation of diluted EPS for the quarters ended March 31, 2008 and 2007 totaled 6.6 million and 3.7 million, respectively.

Note 9 - Restructuring and Other Related Charges

Omnicare Full Potential Program

In 2006, the Company commenced the implementation of the “Omnicare Full Potential” Plan, a major initiative primarily designed to re-engineer the Company’s pharmacy operating model to increase efficiency and enhance

15

customer growth. The Omnicare Full Potential Plan is expected to optimize resources across the entire organization by implementing best practices, including the realignment and right-sizing of functions, and a “hub-and-spoke” model, whereby certain key administrative and production functions will be transferred to regional support centers (“hubs”) specifically designed and managed to perform these tasks, with local pharmacies (“spokes”) focusing on time-sensitive services and customer-facing processes.

This program is expected to be completed over a multi-year period and is estimated to result in total pretax restructuring and other related charges of approximately $93 million. The charges primarily include severance pay, employment agreement buy-outs, excess lease costs and professional fees, as well as other related costs. The Company recorded restructuring and other related charges for the Omnicare Full Potential Plan of approximately $6 million and $9 million pretax (approximately $4 million and $6 million aftertax) during the three months ended March 31, 2008 and 2007, respectively. The Omnicare Full Potential Plan initiatives required cumulative restructuring and other related charges of approximately $53 million before taxes through the first quarter of 2008. The remainder of the overall restructuring and other related charges will be recognized and disclosed prospectively as various phases of the project are finalized and implemented. The Company estimates that the program has led to a reduction in force of approximately 1,200 positions as of March 31, 2008, associated primarily with its pharmacy operations.

The restructuring charges primarily include severance pay, the buy-out of employment agreements, lease terminations, and other exit-related asset disposals, professional fees and facility exit costs. The other related charges are primarily comprised of professional fees. Details of the Omnicare Full Potential Plan restructuring and other related charges follow (pretax, in thousands):

Restructuring charges:	Balance at December 31, 2007		2008 Provision/ Accrual		Utilized during 2008			Balance at March 31, 2008
Employee severance	$	35	$	1,044	$	(1,079	)	$	-
Employment agreement buy-outs		1,199		206		(513	)		892
Lease terminations		3,128		761		(863	)		3,026
Other assets, fees and facility exit costs		1,858		3,694		(2,395	)		3,157
Total restructuring charges	$	6,220		5,705	$	(4,850	)	$	7,075
Other related charges				743
Total restructuring and other related charges			$	6,448

As of March 31, 2008, the Company has made cumulative payments of approximately $11.7 million of severance and other employee-related costs for the Omnicare Full Potential Plan. The remaining liabilities at March 31, 2008, represent amounts not yet paid relating to actions taken in connection with the program (primarily employment agreement buy-out related payments, lease payments and professional fees) and will be settled as these matters are finalized. The provision/accrual and corresponding payment amounts relating to employee severance are being accounted for primarily in accordance with SFAS No. 112 “Employers’ Accounting for Postemployment Benefits;” and the provision/accrual and corresponding payment amounts relating to employment agreement buy-outs are being accounted for primarily in accordance with SFAS No. 146 “Accounting for Costs Associated with Exit or Disposal Activities” (“SFAS 146”).

16

2005 Program

In connection with the previously disclosed consolidation plans and other productivity initiatives to streamline pharmacy services (related, in part, to the NeighborCare, Inc. acquisition) and contract research organization operations, including maximizing workforce and operating asset utilization, and producing a more cost-efficient, operating infrastructure (the “2005 Program”), the Company had liabilities of $5.3 million at December 31, 2007, of which $0.5 million was utilized in the three months ended March 31, 2008. The remaining liabilities of $4.8 million at March 31, 2008 represent amounts not yet paid relating to actions taken in connection with the program (primarily lease payments) and will be settled as these matters are finalized.

Note 10 - Commitments and Contingencies

Omnicare continuously evaluates contingencies based upon the best available information. The Company believes that liabilities have been provided to the extent necessary in cases where the outcome is considered probable and reasonably estimable. To the extent that resolution of contingencies results in amounts that vary from the Company’s recorded liabilities, future earnings will be charged or credited accordingly.

The United States Attorney’s Office, District of Massachusetts, is conducting an investigation relating to the Company’s relationships with certain manufacturers and distributors of pharmaceutical products and certain customers, as well as with respect to contracts with certain companies acquired by the Company. Any action by the U.S. Attorney’s Office, District of Massachusetts, could result in civil or criminal proceedings against the Company. The Company believes that it has complied with all applicable laws and regulations with respect to these matters.

The federal government and certain states had been investigating allegations relating to three generic pharmaceuticals provided by the Company in connection with the substitution of capsules for tablets (Ranitidine), tablets for capsules (Fluoxetine) and two 7.5 mg tablets for one 15 mg tablet (Buspirone). On November 14, 2006, the Company entered into a voluntary civil settlement agreement, under which the Company paid the federal government and participating state governments $51 million to satisfy all of the federal and state civil claims and related plaintiff legal fees. The Company recorded a special litigation charge, for the settlement and related legal fees, of $57.5 million pretax ($45.3 million aftertax) in its financial results for 2006 to establish a reserve relating to the aforementioned investigation. The settlement agreement also resulted in the dismissal, with prejudice, of a number of other allegations included in complaints filed by two qui tam relators. Another issue alleged by one of the qui tam relators remains under seal and was not resolved by the settlement. The settlement agreement did not include any finding of wrongdoing or any admission of liability. As part of the settlement agreement, on November 9, 2006, the Company entered into a Corporate Integrity Agreement with the Department of Health and Human Services Office of the Inspector General with a term of five years from November 9, 2006. The Corporate Integrity Agreement requires that the Company maintain its compliance program in accordance with the terms of the Corporate Integrity Agreement. The agreement contains specific requirements regarding the development and implementation of therapeutic interchange programs and the general training of certain Company employees as to the requirements of the Company’s compliance program and the Corporate Integrity Agreement. The requirements of the Corporate Integrity Agreement have resulted in increased costs to maintain the Company’s compliance program and could result in greater scrutiny by federal regulatory authorities. Violations of the Corporate Integrity Agreement could subject the Company to significant monetary and/or administrative penalties.

On July 11, 2006, the Attorney General’s Office in Michigan provided the Company’s legal counsel with information concerning its investigation relating to certain billing issues under the Michigan Medicaid program

17

at Specialized Pharmacy Services, a subsidiary of the Company located in Michigan. On October 5, 2006, the Company entered into a voluntary settlement agreement and a two-year Corporate Integrity Agreement with the State of Michigan to resolve the Michigan Attorney General’s investigation relating to certain billing issues under the Michigan Medicaid program at Specialized Pharmacy Services. Under the terms of the settlement agreement, the Company paid the State of Michigan approximately $43 million, with an additional amount of approximately $6 million to be paid over the following three years. The Company also reached an agreement in principle with the State of Michigan to resolve claims relating to billing by Specialized Pharmacy Services for drugs provided to hospice patients for a settlement amount of approximately $3.5 million. On October 26, 2007, the Company entered into settlement agreements with the federal government and the State of Michigan to resolve these hospice claims. Under the terms of the October 26, 2007 settlement agreements, the Company paid the federal government and the State of Michigan an aggregate amount of approximately $3.5 million. In connection with the settlements, the November 9, 2006 Corporate Integrity Agreement with the Department of Health and Human Services Office of the Inspector General was also amended to cover certain hospice billing matters. The settlement agreements do not include any finding of wrongdoing or any admission of liability. The Company recorded a special litigation charge of $54.0 million pretax ($46.7 million aftertax) in its financial results for 2006 based on the terms of the settlement agreement. The Corporate Integrity Agreement with the State of Michigan requires that the Company and Specialized Pharmacy Services maintain Specialized Pharmacy Services’ compliance program in accordance with the terms of the Corporate Integrity Agreement. The agreement contains specific requirements regarding compliance with Medicaid policies governing access to pharmacy facilities and records, unit dose billing agreements, consumption billing, hospice patient terminal illness prescriptions and prescriptions dispensed after a patient’s death. The requirements of the Corporate Integrity Agreement have resulted in increased costs to maintain Specialized Pharmacy Services’ compliance program and could result in greater scrutiny by Michigan regulatory authorities. Violations of the Corporate Integrity Agreement could subject the Company to significant monetary and/or administrative penalties.

On February 2 and February 13, 2006, respectively, two substantially similar putative class action lawsuits, entitled Indiana State Dist. Council of Laborers & HOD Carriers Pension & Welfare Fund v. Omnicare, Inc., et al., No. 2:06cv26 (“HOD Carriers”), and Chi v. Omnicare, Inc., et al., No. 2:06cv31 (“Chi”), were filed against Omnicare and two of its officers in the United States District Court for the Eastern District of Kentucky purporting to assert claims for violation of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, and seeking, among other things, compensatory damages and injunctive relief. The complaints, which purported to be brought on behalf of all open-market purchasers of Omnicare common stock from August 3, 2005 through January 27, 2006, alleged that Omnicare had artificially inflated its earnings by engaging in improper generic drug substitution and that defendants had made false and misleading statements regarding the Company’s business and prospects. On April 3, 2006, plaintiffs in the HOD Carriers case formally moved for consolidation and the appointment of lead plaintiff and lead counsel pursuant to the Private Securities Litigation Reform Act of 1995. On May 22, 2006, that motion was granted, the cases were consolidated, and a lead plaintiff and lead counsel were appointed. On July 20, 2006, plaintiffs filed a consolidated amended complaint, adding a third officer as a defendant and new factual allegations primarily relating to revenue recognition, the valuation of receivables and the valuation of inventories. On October 31, 2006, plaintiffs moved for leave to file a second amended complaint, which was granted on January 26, 2007, on the condition that no further amendments would be permitted absent extraordinary circumstances. Plaintiffs thereafter filed their second amended complaint on January 29, 2007. The second amended complaint (i) expands the putative class to include all purchasers of Omnicare common stock from August 3, 2005 through July 27, 2006, (ii) names two members of the Company’s board of directors as additional defendants, (iii) adds a new plaintiff and a new claim for violation of Section 11 of the Securities Act of 1933 based on alleged false and misleading statements in the registration statement filed in connection with the Company’s December 2005 public offering, (iv) alleges that the Company failed to timely disclose its contractual dispute with UnitedHealth, and (v) alleges that the Company failed to timely record certain special litigation reserves.

18

Defendants filed a motion to dismiss the second amended complaint on March 12, 2007, claiming that plaintiffs had failed adequately to plead loss causation, scienter or any actionable misstatement or omission. That motion was fully briefed as of May 1, 2007. In response to certain arguments relating to the individual claims of the named plaintiffs that were raised in defendants’ pending motion to dismiss, plaintiffs filed a motion to add, or in the alternative, to intervene an additional named plaintiff, Alaska Electrical Pension Fund, on July 27, 2007. On October 12, 2007, the court issued an opinion and order dismissing the case and denying plaintiffs’ motion to add an additional named plaintiff. On November 9, 2007, plaintiffs filed a notice of appeal with the United States Court of Appeals for the Sixth Circuit and in a subsequent filing expressed an intention to appeal all aspects of the lower court’s decision. The appellate court has issued a briefing schedule, plaintiffs obtained a 30-day extension of time to file their briefs, and all briefs are now due by May 30, 2008. Oral argument on this appeal has not been scheduled.

On February 13, 2006, two substantially similar shareholder derivative actions, entitled Isak v. Gemunder, et al., Case No. 06-CI-390, and Fragnoli v. Hutton, et al., Case No. 06-CI-389, were filed in Kentucky State Circuit Court, Kenton Circuit, against the members of Omnicare’s board of directors, individually, purporting to assert claims for breach of fiduciary duty, abuse of control, gross mismanagement, waste of corporate assets and unjust enrichment arising out of the Company’s alleged violations of federal and state health care laws based upon the same purportedly improper generic drug substitution that is the subject of the federal purported class action lawsuits. The complaints seek, among other things, damages, restitution and injunctive relief. The Isak and Fragnoli actions were later consolidated by agreement of the parties. On January 12, 2007, the defendants filed a motion to dismiss the consolidated action on the grounds that the dismissal of the substantially identical shareholder derivative action, Irwinv. Gemunder, et al., 2:06cv62, by the United States District Court for the Eastern District of Kentucky on November 20, 2006 should be given preclusive effect and thus bars re-litigation of the issues already decided in Irwin. Instead of opposing that motion, on March 16, 2007, the plaintiffs filed an amended consolidated complaint, which continues to name all of the directors as defendants and asserts the same claims, but attempts to bolster those claims by adding nearly all of the substantive allegations from the most recent complaint in the federal securities class action (see discussion of HOD Carriers above) and an amended complaint in Irwin that added the same factual allegations that were added to the consolidated amended complaint in the HOD Carriers action. On April 16, 2007, defendants filed a supplemental memorandum of law in further support of their pending motion to dismiss contending that the amended complaint should be dismissed on the same grounds previously articulated for dismissal, namely, the preclusive effect of the dismissal of the Irwin action. That motion has been fully briefed, oral argument was held on August 21, 2007, and the court reserved decision.

The Company believes the above-described purported class and derivative actions are without merit and will be vigorously defended.

The three months ended March 31, 2008 and 2007 included a $21.6 million and $6.9 million pretax charge ($13.0 million and $4.3 million after taxes), respectively, reflected in the “Litigation and other related professional fees” line of the Consolidated Statements of Income, for litigation-related professional expenses in connection with the Company’s lawsuit against United, certain other large customer disputes, the administrative subpoenas from the United States Attorney’s Office, District of Massachusetts, the purported class and derivative actions, the investigation by the federal government and certain states relating to drug substitutions, the Company’s response to subpoenas it received relating to other legal proceedings to which the Company is not a party, and the inquiry conducted by the Attorney General’s Office in Michigan relating to certain billing issues under the Michigan Medicaid program.

During 2006, the Company experienced certain quality control and product recall issues, as well as fire damage, at one of its repackaging facilities, Heartland Repack Services (“Heartland”). As a precautionary measure, the

19

Company voluntarily and temporarily suspended operations at Heartland. During the time that the Heartland facility was closed, the Company conducted certain environmental tests at the facility. Based on the results of these tests, which showed very low levels of beta lactam residue, and the time and expense associated with completing the necessary remediation procedures, as well as the short remaining term on the lease for the current facility, the Company decided not to reopen the Heartland facility. The Company continues to work to address and resolve all issues, and restore centralized repackaging to full capacity. In order to temporarily replace the capacity of the Heartland facility, the Company ramped up production in its other repackaging facility, as well as onsite in its individual pharmacies for use by their patients. As a result, the Company has been and continues to be able to meet the needs of all of its client facilities and their residents. Addressing these issues served to increase costs and as a result, the three months ended March 31, 2008 included special charges of approximately $1.9 million pretax ($1.6 million and $0.3 million was recorded in the cost of sales and operating expenses sections of the Consolidated Statements of Income, respectively) ($1.1 million after taxes) for costs associated with the quality control, product recall and fire damage issues at Heartland. The associated costs for the three months ended March 31, 2007 totaled approximately $5.8 million pretax ($4.3 million and $1.5 million was recorded in the cost of sales and operating expenses sections of the Consolidated Statements of Income, respectively) ($3.6 million after taxes). The Company maintains product recall, property and casualty and business interruption insurance, and the extent of insurance recovery for these expenses continues to be reviewed by its outside advisors. As of March 31, 2008, no receivables for insurance recoveries have been recorded by the Company. Further, in order to replace the repackaging capacity of the Heartland facility, on February 27, 2007, Omnicare entered into an agreement for the Repackaging Services division of Cardinal Health to serve as the contract repackager for pharmaceutical volumes previously repackaged at the Heartland facility. The agreement initially extends through October 2010.

Although the Company cannot know with certainty the ultimate outcome of the matters described in the preceding paragraphs, there can be no assurance that the resolution of these matters will not have a material adverse impact on the Company’s consolidated results of operations, financial position or cash flows or, in the case of the investigations regarding certain drug substitutions and the matters relating to the Heartland facility, that these matters will be resolved in an amount that would not exceed the amount of the pretax charges recorded by the Company.

As part of its ongoing operations, the Company is subject to various inspections, audits, inquiries and similar actions by third parties, as well as governmental/regulatory authorities responsible for enforcing the laws and regulations to which the Company is subject. The Company is also involved in various legal actions arising in the normal course of business. These matters are continuously being evaluated and, in many cases, are being contested by the Company and the outcome is not predictable. Consequently, an estimate of the possible loss or range of loss associated with certain actions cannot be made. Although occasional adverse outcomes (or settlements) may occur and could possibly have an adverse effect on the results of operations and cash flows in any one accounting period, outside of the matters described in the preceding paragraphs, the Company is not aware of any such matters whereby it is presently believed that the final disposition will have a material adverse affect on the Company’s overall consolidated financial position.

The Company indemnifies the directors and officers of the Company for certain liabilities that might arise from the performance of their job responsibilities for the Company. Additionally, in the normal course of business, the Company enters into contracts that contain a variety of representations and warranties and which provide general indemnifications. The Company’s maximum exposure under these arrangements is unknown, as this involves the resolution of claims made, or future claims that may be made, against the Company, its directors and/or officers, the outcomes of which is unknown and not currently predictable. Accordingly, no liabilities have been recorded for the indemnifications.

20

Note 11 - Segment Information

Based on the “management approach,” as defined by SFAS No. 131, “Disclosures about Segments of an Enterprise and Related Information,” Omnicare has two operating segments. The Company’s larger segment is Pharmacy Services. Pharmacy Services primarily provides distribution of pharmaceuticals, related pharmacy consulting and other ancillary services, data management services, medical supplies, and distribution and patient assistance services for specialty pharmaceuticals. The Company’s customers are primarily skilled nursing, assisted living, hospice and other providers of healthcare services in 47 states in the United States, the District of Columbia and in Canada at March 31, 2008. The Company’s other segment is CRO Services, which provides comprehensive product development and research services to client companies in pharmaceutical, biotechnology, medical devices and diagnostics industries in 30 countries around the world at March 31, 2008, including the United States. Certain reclassification of prior-year depreciation and amortization amounts have been made to conform with the current-year presentation.

The table below presents information about the segments as of and for the three months ended March 31, 2008 and 2007, and should be read in conjunction with the paragraph that follows (in thousands):

	Three months ended March 31,
2008:	Pharmacy Services			CRO Services			Corporate and Consolidating			Consolidated Totals
Net sales	$	1,509,806		$	49,173		$	-		$	1,558,979
Depreciation and amortization		(20,239	)		(439	)		(8,837	)		(29,515	)
Restructuring and other related      charges		(5,096	)		(774	)		(578	)		(6,448	)
Litigation and other related professional fees		(21,642	)		-			-			(21,642	)
Heartland matters		(1,893	)		-			-			(1,893	)
Operating income (expense)		109,235			2,668			(27,659	)		84,244
Total assets		6,917,435			187,168			469,489			7,574,092
Capital expenditures		(11,924	)		(342	)		(173	)		(12,439	)
2007:
Net sales	$	1,529,643		$	47,422		$	-		$	1,577,065
Depreciation and amortization		(21,611	)		(477	)		(6,634	)		(28,722	)
Restructuring and other related      charges		(4,752	)		(1,818	)		(2,604	)		(9,174	)
Litigation and other related professional fees		(6,907	)		-			-			(6,907	)
Heartland matters		(5,792	)		-			-			(5,792	)
Operating income (expense)		135,590			730			(26,634	)		109,686
Total assets		7,029,228			175,004			337,465			7,541,697
Capital expenditures		(7,471	)		(274	)		(536	)		(8,281	)

In accordance with Emerging Issues Task Force (“EITF”) Issue No. 01-14, “Income Statement Characterization of Reimbursements Received for “Out-of-Pocket” Expenses Incurred” (“EITF No. 01-14”), Omnicare included in its reported CRO segment net sales amount, for the three month periods ended March 31, 2008 and 2007, reimbursable out-of-pockets totaling $7.4 million and $7.3 million, respectively.

21

Note 12 - Guarantor Subsidiaries

The Company’s 6.125% senior subordinated notes due 2013, the 6.75% senior subordinated notes due 2013 and the 6.875% senior subordinated notes due 2015 are fully and unconditionally guaranteed on an unsecured, joint and several basis by certain wholly-owned subsidiaries of the Company (the “Guarantor Subsidiaries”). The following condensed consolidating financial data illustrates the composition of Omnicare, Inc. (“Parent”), the Guarantor Subsidiaries and the Non-Guarantor Subsidiaries as of March 31, 2008 and December 31, 2007 for the balance sheets, as well as the statements of income and the statements of cash flows for the three months ended March 31, 2008 and 2007. Separate complete financial statements of the respective Guarantor Subsidiaries would not provide information that would be necessary for evaluating the sufficiency of the Guarantor Subsidiaries, and thus are not presented. No consolidating/eliminating adjustment column is presented for the condensed consolidating statements of cash flows since there were no significant consolidating/eliminating adjustment amounts during the periods presented.

22

Summary Consolidating Statements of Income - Unaudited
(in thousands)
	Three months ended March 31,
2008:	Parent			Guarantor Subsidiaries			Non- Guarantor Subsidiaries			Consolidating/ Eliminating Adjustments			Omnicare, Inc. and Subsidiaries
Net sales	$	-		$	1,498,685		$	60,294		$	-		$	1,558,979
Cost of sales		-			1,131,614			46,149			-			1,177,763
Heartland matters		-			1,574			-			-			1,574
Gross profit		-			365,497			14,145			-			379,642
Selling, general and administrative      expenses		1,948			224,995			9,654			-			236,597
Provision for doubtful accounts		-			29,051			1,341			-			30,392
Restructuring and other related charges		-			6,448			-			-			6,448
Litigation and other related professional fees		-			21,642			-			-			21,642
Heartland matters		-			319			-			-			319
Operating income (loss)		(1,948	)		83,042			3,150			-			84,244
Investment income		574			2,037			-			-			2,611
Interest expense		(34,985	)		(1,155	)		(916	)		-			(37,056	)
Income (loss) before income taxes		(36,359	)		83,924			2,234			-			49,799
Income tax (benefit) expense		(14,496	)		33,460			891			-			19,855
Equity in net income of subsidiaries		51,807			-			-			(51,807	)		-
Net income	$	29,944		$	50,464		$	1,343		$	(51,807	)	$	29,944
2007:
Net sales		$ -		$	1,520,018		$	57,047		$	-		$	1,577,065
Cost of sales		-			1,148,700			42,293			-			1,190,993
Heartland matters		-			4,296			-			-			4,296
Gross profit		-			367,022			14,754			-			381,776
Selling, general and administrative      expenses		2,133			214,067			9,409			-			225,609
Provision for doubtful accounts		-			28,462			442						28,904
Restructuring and other related charges		-			8,264			910			-			9,174
Litigation and other related professional fees		-			6,907			-			-			6,907
Heartland matters		-			1,496			-			-			1,496
Operating income (loss)		(2,133	)		107,826			3,993			-			109,686
Investment income		571			1,350			-			-			1,921
Interest expense		(41,006	)		(276	)		(766	)		-			(42,048	)
Income (loss) before income taxes		(42,568	)		108,900			3,227			-			69,559
Income tax (benefit) expense		(16,261	)		41,600			1,233			-			26,572
Equity in net income of subsidiaries		69,294			-			-			(69,294	)		-
Net income	$	42,987		$	67,300		$	1,994		$	(69,294	)	$	42,987

23

Note 12 - Guarantor Subsidiaries (Continued)

Condensed Consolidating Balance Sheets
(in thousands)
As of March 31, 2008 (Unaudited):	Parent		Guarantor Subsidiaries		Non- Guarantor Subsidiaries		Consolidating/ Eliminating Adjustments			Omnicare, Inc. and Subsidiaries
ASSETS
Cash and cash equivalents	$	217,350	$	60,393	$	23,517	$	-		$	301,260
Restricted cash		-		14,764		-		-			14,764
Accounts receivable, net (including intercompany)		-		1,330,057		32,407		(4,728	)		1,357,736
Unbilled receivables, CRO		-		29,740		-		-			29,740
Inventories		-		397,194		11,904		-			409,098
Deferred income tax benefits (liabilities), net-current		-		137,023		-		(3,509	)		133,514
Other current assets		1,566		202,278		5,794		-			209,638
Total current assets		218,916		2,171,449		73,622		(8,237	)		2,455,750
Properties and equipment, net		-		189,436		10,450		-			199,886
Goodwill		-		4,244,023		102,936		-			4,346,959
Identifiable intangible assets, net		-		312,865		5,064		-			317,929
Other noncurrent assets		50,547		203,123		287		(389	)		253,568
Investment in subsidiaries		5,918,334		-		-		(5,918,334	)		-
Total assets	$	6,187,797	$	7,120,896	$	192,359	$	(5,926,960	)	$	7,574,092
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities (including intercompany)	$	55,754	$	556,922	$	25,192	$	(4,728	)	$	633,140
Long-term debt, notes and convertible debentures		2,722,889		3,773		49,437		-			2,776,099
Deferred income tax liabilities, net-noncurrent		79,151		398,307		9,545		(3,509	)		483,494
Other noncurrent liabilities		-		350,651		1,094		(389	)		351,356
Stockholders’ equity		3,330,003		5,811,243		107,091		(5,918,334	)		3,330,003
Total liabilities and stockholders’ equity	$	6,187,797	$	7,120,896	$	192,359	$	(5,926,960	)	$	7,574,092

24

Note 12 - Guarantor Subsidiaries (Continued)

Condensed Consolidating Balance Sheets - (Continued)
(in thousands)
As of December 31, 2007:	Parent		Guarantor Subsidiaries		Non- Guarantor Subsidiaries		Consolidating/ Eliminating Adjustments			Omnicare, Inc. and Subsidiaries
ASSETS
Cash and cash equivalents	$	171,779	$	70,088	$	32,581	$	-		$	274,448
Restricted cash		-		3,155		-		-			3,155
Accounts receivable, net (including intercompany)		-		1,348,504		30,386		(2,602	)		1,376,288
Unbilled receivables, CRO		-		24,855		-		-			24,855
Inventories		-		436,639		11,544		-			448,183
Deferred income tax benefits (liabilities), net-current		878		125,474		-		(113	)		126,239
Other current assets		1,336		196,474		5,172		-			202,982
Total current assets		173,993		2,205,189		79,683		(2,715	)		2,456,150
Properties and equipment, net		-		188,340		11,109		-			199,449
Goodwill		-		4,238,547		103,622		-			4,342,169
Identifiable intangible assets, net		-		318,255		5,382		-			323,637
Other noncurrent assets		52,135		219,906		333		-			272,374
Investment in subsidiaries		5,939,714		-		-		(5,939,714	)		-
Total assets	$	6,165,842	$	7,170,237	$	200,129	$	(5,942,429	)	$	7,593,779
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities (including intercompany)	$	33,105	$	600,095	$	21,562	$	(2,602	)	$	652,160
Long-term debt, notes and convertible debentures		2,764,510		4,505		51,736		-			2,820,751
Deferred income tax liabilities, net-noncurrent		68,534		372,110		9,258		(113	)		449,789
Other noncurrent liabilities		7,990		370,352		1,034		-			379,376
Stockholders’ equity		3,291,703		5,823,175		116,539		(5,939,714	)		3,291,703
Total liabilities and stockholders’ equity	$	6,165,842	$	7,170,237	$	200,129	$	(5,942,429	)	$	7,593,779

25

Note 12 - Guarantor Subsidiaries (Continued)

Condensed Consolidating Statements of Cash Flows - Unaudited
(in thousands)
	Three months ended March 31,
2008:	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Omnicare, Inc. and Subsidiaries
Cash flows from operating activities:
Net cash flows from operating activities	$	10,759		$	142,984		$	(11,479	)	$	142,264
Cash flows from investing activities:
Acquisition of businesses, net of cash received		-			(35,983	)		-			(35,983	)
Capital expenditures		-			(12,242	)		(197	)		(12,439	)
Transfer of cash to trusts for employee health and severance      costs, net of payments out of the trust		-			(11,542	)		-			(11,542	)
Other		-			(32	)		-			(32	)
Net cash flows used by investing activities		-			(59,799	)		(197	)		(59,996	)
Cash flows from financing activities:
Borrowings on line of credit facilities and term A loan		49,000			-			-			49,000
Payments on line of credit facilities and term A loan		(99,000	)		-			-			(99,000	)
Payments on long-term borrowings and obligations		(963	)		-			-			(963	)
Change in cash overdraft balance		(900	)		43			-			(857	)
(Payments) for stock awards and exercise of stock options,      net of stock tendered in payment		(3,584	)		-			-			(3,584	)
Excess tax benefits from stock-based compensation		82			-						82
Dividends paid		(2,746	)		-			-			(2,746	)
Other		92,923			(92,923	)		-			-
Net cash flows from financing activities		34,812			(92,880	)		-			(58,068	)
Effect of exchange rate changes on cash		-			-			2,612			2,612
Net increase (decrease) in cash and cash equivalents		45,571			(9,695	)		(9,064	)		26,812
Cash and cash equivalents at beginning of period		171,779			70,088			32,581			274,448
Cash and cash equivalents at end of period	$	217,350		$	60,393		$	23,517		$	301,260

26

Note 12 - Guarantor Subsidiaries (Continued)

Condensed Consolidating Statements of Cash Flows - (Continued) - Unaudited
(in thousands)
	Three months ended March 31,
2007:	Parent			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Omnicare, Inc. and Subsidiaries
Cash flows from operating activities:
Net cash flows from operating activities	$	9,178		$	159,413		$	6,198		$	174,789
Cash flows from investing activities:
Acquisition of businesses, net of cash received		-			(43,305	)		-			(43,305	)
Capital expenditures		-			(7,592	)		(689	)		(8,281	)
Transfer of cash to trusts for employee health and severance      costs, net of payments out of the trust		-			(10,322	)		-			(10,322	)
Other		-			(16	)		(8	)		(24	)
Net cash flows used by investing activities		-			(61,235	)		(697	)		(61,932	)
Cash flows from financing activities:
Borrowings on line of credit facilities and term A loan		74,000			-			-			74,000
Payments on line of credit facilities and term A loan		(124,000	)		-			-			(124,000	)
Payments on long-term borrowings and obligations		(1,304	)		-			-			(1,304	)
Change in cash overdraft balance		(5,148	)		(2,838	)		-			(7,986	)
(Payments) for stock awards and exercise of stock options,      net of stock tendered in payment		(8,232	)		-			-			(8,232	)
Excess tax benefits from stock-based compensation		4,063			-			-			4,063
Dividends paid		(2,739	)		-			-			(2,739	)
Other		138,026			(138,026	)		-			-
Net cash flows from financing activities		74,666			(140,864	)		-			(66,198	)
Effect of exchange rate changes on cash		-			-			553			553
Net increase (decrease) in cash and cash equivalents		83,844			(42,686	)		6,054			47,212
Cash and cash equivalents at beginning of period		43,494			74,262			20,278			138,034
Cash and cash equivalents at end of period	$	127,338		$	31,576		$	26,332		$	185,246

27

Note 12 - Guarantor Subsidiaries (Continued)

The Company’s 3.25% convertible senior debentures due 2035 are fully and unconditionally guaranteed on an unsecured basis by Omnicare Purchasing Company, LP, a wholly-owned subsidiary of the Company (the “Guarantor Subsidiary”). The following condensed consolidating financial data illustrates the composition of Omnicare, Inc. (“Parent”), the Guarantor Subsidiary and the Non-Guarantor Subsidiaries as of March 31, 2008 and December 31, 2007 for the balance sheets, as well as the statements of income and the statements of cash flows for the three months ended March 31, 2008 and 2007. Separate complete financial statements of the respective Guarantor Subsidiary would not provide information that would be necessary for evaluating the sufficiency of the Guarantor Subsidiary, and thus are not presented. The Guarantor Subsidiary does not have any material net cash flows in the condensed consolidating statements of cash flows. No consolidating/eliminating adjustments column is presented for the condensed consolidating statements of cash flows since there were no significant consolidating/eliminating adjustment amounts during the periods presented.

28

Summary Consolidating Statements of Income - Unaudited
(in thousands)
	Three months ended March 31,
							Non-			Consolidating/			Omnicare,
				Guarantor			Guarantor			Eliminating			Inc. and
2008:	Parent			Subsidiary			Subsidiaries			Adjustments			Subsidiaries
Net sales	$	-		$	-		$	1,558,979		$	-		$	1,558,979
Cost of sales		-			-			1,177,763			-			1,177,763
Heartland matters		-			-			1,574			-			1,574
Gross profit		-			-			379,642			-			379,642
Selling, general and administrative
expenses		1,948			300			234,349			-			236,597
Provision for doubtful accounts		-			-			30,392			-			30,392
Restructuring and other related charges		-			-			6,448			-			6,448
Litigation and other related professional fees		-			-			21,642			-			21,642
Heartland matters		-			-			319			-			319
Operating income (loss)		(1,948	)		(300	)		86,492			-			84,244
Investment income		574			-			2,037			-			2,611
Interest expense		(34,985	)		-			(2,071	)		-			(37,056	)
Income (loss) before income taxes		(36,359	)		(300	)		86,458			-			49,799
Income tax (benefit) expense		(14,496	)		(120	)		34,471			-			19,855
Equity in net income of subsidiaries		51,807			-			-			(51,807	)		-
Net income (loss)	$	29,944		$	(180	)	$	51,987		$	(51,807	)	$	29,944
2007:
Net sales	$	-		$	-		$	1,577,065		$	-		$	1,577,065
Cost of sales		-			-			1,190,993			-			1,190,993
Heartland matters		-			-			4,296			-			4,296
Gross profit		-			-			381,776			-			381,776
Selling, general and administrative
expenses		2,133			271			223,205			-			225,609
Provision for doubtful accounts		-			-			28,904			-			28,904
Restructuring and other related charges		-			-			9,174			-			9,174
Litigation and other related professional fees		-			-			6,907			-			6,907
Heartland matters		-			-			1,496			-			1,496
Operating income (loss)		(2,133	)		(271	)		112,090			-			109,686
Investment income		571			-			1,350			-			1,921
Interest expense		(41,006	)		-			(1,042	)		-			(42,048	)
Income (loss) before income taxes		(42,568	)		(271	)		112,398			-			69,559
Income tax (benefit) expense		(16,261	)		(104	)		42,937			-			26,572
Equity in net income of subsidiaries		69,294			-			-			(69,294	)		-
Net income (loss)	$	42,987		$	(167	)	$	69,461		$	(69,294	)	$	42,987

29

Note 12 - Guarantor Subsidiaries (Continued)

Condensed Consolidating Balance Sheets
(in thousands)
As of March 31, 2008 (Unaudited):	Parent		Guarantor Subsidiary		Non- Guarantor Subsidiaries		Consolidating/ Eliminating Adjustments			Omnicare, Inc. and Subsidiaries
ASSETS
Cash and cash equivalents	$	217,350	$	-	$	83,910	$	-		$	301,260
Restricted cash		-		-		14,764		-			14,764
Accounts receivable, net (including intercompany)		-		61		1,357,736		(61	)		1,357,736
Unbilled receivables, CRO		-		-		29,740		-			29,740
Inventories		-		-		409,098		-			409,098
Deferred income tax benefits (liabilities), net-current		-		-		136,849		(3,335	)		133,514
Other current assets		1,566		-		208,072		-			209,638
Total current assets		218,916		61		2,240,169		(3,396	)		2,455,750
Properties and equipment, net		-		27		199,859		-			199,886
Goodwill		-		-		4,346,959		-			4,346,959
Identifiable intangible assets, net		-		-		317,929		-			317,929
Other noncurrent assets		50,547		19		203,391		(389	)		253,568
Investment in subsidiaries		5,918,334		-		-		(5,918,334	)		-
Total assets	$	6,187,797	$	107	$	7,308,307	$	(5,922,119	)	$	7,574,092
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities (including intercompany)	$	55,754	$	1	$	577,446	$	(61	)	$	633,140
Long-term debt, notes and convertible debentures		2,722,889		-		53,210		-			2,776,099
Deferred income tax liabilities, net-noncurrent		79,151		-		407,678		(3,335	)		483,494
Other noncurrent liabilities		-		-		351,745		(389	)		351,356
Stockholders’ equity		3,330,003		106		5,918,228		(5,918,334	)		3,330,003
Total liabilities and stockholders’ equity	$	6,187,797	$	107	$	7,308,307	$	(5,922,119	)	$	7,574,092

30

Note 12 - Guarantor Subsidiaries (Continued)

Condensed Consolidating Balance Sheets - (Continued)
(in thousands)
As of December 31, 2007:	Parent		Guarantor Subsidiary		Non- Guarantor Subsidiaries		Consolidating/ Eliminating Adjustments			Omnicare, Inc. and Subsidiaries
ASSETS
Cash and cash equivalents	$	171,779	$	-	$	102,669	$	-		$	274,448
Restricted cash		-		-		3,155		-			3,155
Accounts receivable, net (including intercompany)		-		43		1,376,288		(43	)		1,376,288
Unbilled receivables, CRO		-		-		24,855		-			24,855
Inventories		-		-		448,183		-			448,183
Deferred income tax benefits (liabilities), net-current		878		-		125,361		-			126,239
Other current assets		1,336		-		201,646		-			202,982
Total current assets		173,993		43		2,282,157		(43	)		2,456,150
Properties and equipment, net		-		28		199,421		-			199,449
Goodwill		-		-		4,342,169		-			4,342,169
Identifiable intangible assets, net		-		-		323,637		-			323,637
Other noncurrent assets		52,135		19		220,220		-			272,374
Investment in subsidiaries		5,939,714		-		-		(5,939,714	)		-
Total assets	$	6,165,842	$	90	$	7,367,604	$	(5,939,757	)	$	7,593,779
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities (including intercompany)	$	33,105	$	-	$	619,098	$	(43	)	$	652,160
Long-term debt, notes and convertible debentures		2,764,510		-		56,241		-			2,820,751
Deferred income tax liabilities, net-noncurrent		68,534		-		381,255		-			449,789
Other noncurrent liabilities		7,990		-		371,386		-			379,376
Stockholders’ equity		3,291,703		90		5,939,624		(5,939,714	)		3,291,703
Total liabilities and stockholders’ equity	$	6,165,842	$	90	$	7,367,604	$	(5,939,757	)	$	7,593,779

31

Note 12 - Guarantor Subsidiaries (Continued)

Condensed Consolidating Statements of Cash Flows - Unaudited
(in thousands)
	Three months ended March 31,
2008:	Parent			Guarantor Subsidiary		Non-Guarantor Subsidiaries			Omnicare, Inc. and Subsidiaries
Cash flows from operating activities:
Net cash flows from operating activities	$	10,759		$	-	$	131,505		$	142,264
Cash flows from investing activities:
Acquisition of businesses, net of cash received		-			-		(35,983	)		(35,983	)
Capital expenditures		-			-		(12,439	)		(12,439	)
Transfer of cash to trusts for employee health and severance      costs, net of payments out of the trust		-			-		(11,542	)		(11,542	)
Other		-			-		(32	)		(32	)
Net cash flows used by investing activities		-			-		(59,996	)		(59,996	)
Cash flows from financing activities:
Borrowings on line of credit facilities and term A loan		49,000			-		-			49,000
Payments on line of credit facilities and term A loan		(99,000	)		-		-			(99,000	)
Payments on long-term borrowings and obligations		(963	)		-		-			(963	)
Change in cash overdraft balance		(900	)		-		43			(857	)
(Payments) for stock awards and exercise of stock options,      net of stock tendered in payment		(3,584	)		-		-			(3,584	)
Excess tax benefits from stock-based compensation		82			-		-			82
Dividends paid		(2,746	)		-		-			(2,746	)
Other		92,923			-		(92,923	)		-
Net cash flows from financing activities		34,812			-		(92,880	)		(58,068	)
Effect of exchange rate changes on cash		-			-		2,612			2,612
Net increase (decrease) in cash and cash equivalents		45,571			-		(18,759	)		26,812
Cash and cash equivalents at beginning of period		171,779			-		102,669			274,448
Cash and cash equivalents at end of period	$	217,350		$	-	$	83,910		$	301,260

32

Note 12 - Guarantor Subsidiaries (Continued)

Condensed Consolidating Statements of Cash Flows - (Continued) - Unaudited
(in thousands)
	Three months ended March 31,
2007:	Parent			Guarantor Subsidiary		Non-Guarantor Subsidiaries			Omnicare, Inc. and Subsidiaries
Cash flows from operating activities:
Net cash flows from operating activities	$	9,178		$	-	$	165,611		$	174,789
Cash flows from investing activities:
Acquisition of businesses, net of cash received		-			-		(43,305	)		(43,305	)
Capital expenditures		-			-		(8,281	)		(8,281	)
Transfer of cash to trusts for employee health and severance      costs, net of payments out of the trust		-			-		(10,322	)		(10,322	)
Other		-			-		(24	)		(24	)
Net cash flows used by investing activities		-			-		(61,932	)		(61,932	)
Cash flows from financing activities:
Borrowings on line of credit facilities and term A loan		74,000			-		-			74,000
Payments on line of credit facilities and term A loan		(124,000	)		-		-			(124,000	)
Payments on long-term borrowings and obligations		(1,304	)		-		-			(1,304	)
Change in cash overdraft balance		(5,148	)		-		(2,838	)		(7,986	)
(Payments) for stock awards and exercise of stock options,      net of stock tendered in payment		(8,232	)		-		-			(8,232	)
Excess tax benefits from stock-based compensation		4,063			-		-			4,063
Dividends paid		(2,739	)		-		-			(2,739	)
Other		138,026			-		(138,026	)		-
Net cash flows from financing activities		74,666			-		(140,864	)		(66,198	)
Effect of exchange rate changes on cash		-			-		553			553
Net increase (decrease) in cash and cash equivalents		83,844			-		(36,632	)		47,212
Cash and cash equivalents at beginning of period		43,494			-		94,540			138,034
Cash and cash equivalents at end of period	$	127,338		$	-	$	57,908		$	185,246

33

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (“MD&A”)

The following discussion should be read in conjunction with the Consolidated Financial Statements, related notes and other financial information appearing elsewhere in this report. In addition, see “Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information.” The reader should also refer to the Consolidated Financial Statements and notes thereto and MD&A, including critical accounting policies, for the year ended December 31, 2007, which appear in the Company’s Annual Report on Form 10-K, (“Omnicare’s 2007 Annual Report”), which was filed with the Securities and Exchange Commission on February 28, 2008.

Overview of Three Months Ended March 31, 2008 and Results of Operations

Omnicare, Inc. (“Omnicare” or the “Company”) is a leading geriatric pharmaceutical services company. Omnicare is the nation’s largest provider of pharmaceuticals and related pharmacy and ancillary services to long-term healthcare institutions. Omnicare’s clients include primarily skilled nursing facilities (“SNFs”), assisted living facilities, retirement centers, independent living communities, hospitals, hospice, and other healthcare settings and service providers. At March 31, 2008, Omnicare served long-term care facilities as well as chronic care and other settings comprising approximately 1,446,000 beds, including approximately 69,000 patients served by the patient assistance programs of its specialty pharmacy business that had not previously been included. The comparable number at December 31, 2007 was 1,449,000 (including 57,000 specialty pharmacy patients) and 1,468,000 (including 68,000 specialty pharmacy patients) at March 31, 2007. Omnicare provides its pharmacy services in 47 states in the United States, the District of Columbia and Canada at March 31, 2008. As well, Omnicare provides operational software and support systems to long-term care pharmacy providers across the United States. Omnicare’s pharmacy services also include distribution and patient assistance services for specialty pharmaceuticals. Omnicare provides comprehensive product development and research services for the pharmaceutical, biotechnology, medical device and diagnostic industries in 30 countries worldwide.

The following summary table presents consolidated net sales and results of operations of Omnicare for the three months ended March 31, 2008 and 2007 (in thousands, except per share amounts). In accordance with the Securities and Exchange Commission (“SEC”) release entitled “Conditions for Use of Non-GAAP Financial Measures,” the Company has disclosed in this MD&A, with the exception of EBITDA (discussed below), only those measures that are in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”).

34

	Three months ended March 31,
	2008			2007
Net sales	$	1,558,979		$	1,577,065
Net income	$	29,944		$	42,987
Earnings per share:
Basic	$	0.25		$	0.36
Diluted	$	0.25		$	0.35
EBITDA(a)	$	113,759		$	138,408
EBITDA reconciliation to net cash flows
from operating activities:
EBITDA(a)	$	113,759		$	138,408
(Subtract)/Add:
Interest expense, net of investment income		(34,445	)		(40,127	)
Income tax provision		(19,855	)		(26,572	)
Changes in assets and liabilities, net of
effects from acquisition of businesses		28,436			60,919
Provision for doubtful accounts		30,392			28,904
Deferred tax provision		23,977			13,257
Net cash flows from operating activities	$	142,264		$	174,789

(a) “EBITDA” represents earnings before interest (net of investment income), income taxes, depreciation and amortization. Omnicare uses EBITDA primarily as an indicator of the Company’s ability to service its debt, and believes that certain investors find EBITDA to be a useful financial measure for the same purpose. However, EBITDA does not represent net cash flows from operating activities, as defined by U.S. GAAP, and should not be considered as a substitute for operating cash flows as a measure of liquidity. The Company’s calculation of EBITDA may differ from the calculation of EBITDA by others.

Three Months Ended March 31, 2008 vs. 2007

Total net sales for the three months ended March 31, 2008 decreased to $1,559.0 million from $1,577.1 million in the comparable prior-year period. Net income for the three months ended March 31, 2008 was $29.9 million versus $43.0 million earned in the comparable 2007 period. Diluted earnings per share for the three months ended March 31, 2008 were $0.25 versus $0.35 in the same prior-year period. EBITDA totaled $113.8 million for the three months ended March 31, 2008 as compared with $138.4 million for the same period of 2007.

35

The Company continues to be impacted by the unilateral reduction in April 2006 by UnitedHealth Group, Inc. and its Affiliates (“United”) in the reimbursement rates paid by United to Omnicare by switching to its PacifiCare pharmacy network contract for services rendered by Omnicare to beneficiaries of United’s drug benefit plans under the Medicare Part D program. The differential in reimbursement rates that resulted from United’s action, as compared with reimbursement rates under the originally negotiated contract, reduced sales and operating profit in the first quarter of 2008 by approximately $23.9 million (approximately $14.4 million aftertax), and cumulatively since April 2006 by approximately $222.7 million (approximately $138.8 million aftertax). This matter is currently the subject of litigation initiated by Omnicare and is before the federal court in the Northern District of Illinois. See further discussion at the “Legal Proceedings” section at Part II, Item 1 of this Filing.

Net sales for the quarter were unfavorably impacted by a lower number of beds served, combined with a year-over-year shift in mix towards assisted living, the increased availability and utilization of generic drugs, reductions in reimbursement and/or utilization for certain drugs as well as competitive pricing issues, and lower revenues reported from copays and rejects under Part D as well as from certain matters currently in litigation. Partially offsetting these factors was the favorable impact of drug price inflation, acquisitions, increased drug utilization and year-over-year growth in CRO Services revenues. See discussion of sales and operating profit results in more detail at the “Pharmacy Services Segment” and “CRO Services Segment” captions below.

The Company’s consolidated gross profit of $379.6 million decreased $2.2 million for the three months ended March 31, 2008, from the same prior-year period amount of $381.8 million. Gross profit as a percentage of total net sales of 24.4% in the three months ended March 31, 2008, was higher than the 24.2% experienced during the comparable 2007 period. Gross profit was favorably impacted in the 2008 period largely as a result of lower incremental costs associated with the closure of the Company’s Heartland repackaging facility as further described below, the increased availability and utilization of higher margin generic drugs, purchasing improvements, the favorable effect of drug price inflation and the continued integration of prior-period acquisitions. Offsetting these factors was the gross profit impact of the aforementioned reduction in net sales, primarily the lower net number of beds served, and the reductions in reimbursement.

Omnicare’s consolidated selling, general and administrative (“operating”) expenses for the three months ended March 31, 2008 of $236.6 million were higher than the comparable prior-year amount of $225.6 million by $11.0 million. Operating expenses as a percentage of net sales amounted to 15.2% in the first quarter of 2008, representing an increase from the 14.3% experienced in the comparable prior-year period. Operating expenses for the quarter ended March 31, 2008 were unfavorably impacted largely by increases in professional fees, employee benefit costs, and increased operating costs associated with recent acquisitions. Partially offsetting the increased operating expenses were the favorable impact of the Company’s continued integration of prior-year acquisitions, purchasing improvements and productivity enhancements.

36

The provision for doubtful accounts for the three months ended March 31, 2008 of $30.4 million was $1.5 million higher than the comparable prior year amount of $28.9 million.

Investment income for the three months ended March 31, 2008 of $2.6 million was higher than the $1.9 million earned in the comparable prior-year period, primarily due to higher average invested balances versus the prior year.

Interest expense for the three months ended March 31, 2008 of $37.1 million is lower than the $42.0 million in the comparable prior-year period, primarily due to lower debt outstanding resulting from payments aggregating $200 million on the Company’s senior term A loan facility, maturing on July 28, 2010 (the “Term Loans”) throughout 2007 and the first three months of 2008 and lower interest rates on variable rate loans.

The effective income tax rate was 39.9% for the three months ended March 31, 2008, as compared to the first quarter of 2007 rate of 38.2% . The year-over-year increase in the effective tax rate is primarily attributable to the impact of state legislative changes and a reduction in the benefit of state net operating losses. The effective tax rates in 2008 and 2007 are higher than the federal statutory rate largely as a result of the impact of state and local income taxes and various nondeductible expenses.

Special Items:

The three months ended March 31, 2008 included the following charges, which primarily impacted the Pharmacy Services segment. Management believes that these special items are either infrequent occurrences or otherwise not related to Omnicare’s ordinary course of business:

(i) Operating income included restructuring and other related charges of approximately $6.4 million pretax ($3.9 million aftertax), relating to the implementation of the “Omnicare Full Potential” Plan, a major initiative primarily designed to re-engineer the pharmacy operating model to increase efficiency and enhance customer growth. See further discussion at the “Restructuring and Other Related Charges” note of the Notes to Consolidated Financial Statements and the “Restructuring and Other Related Charges” section of this MD&A.

(ii) During 2006, the Company experienced certain quality control and product recall issues, as well as fire damage, at one of its repackaging facilities, Heartland Repack Services (“Heartland”), as described in further detail at the “Commitments and Contingencies” note of the Notes to Consolidated Financial Statements (the “Heartland Matters”). In addressing and resolving these Heartland Matters, the Company continues to experience increased costs and as a result, the three months ended March 31, 2008 included special charges of $1.9 million pretax (approximately $1.6 million and $0.3 million was recorded in the cost of sales and operating expense sections of the Consolidated Statements of Income, respectively) ($1.1 million aftertax) for these increased costs. The Company maintains product recall, property and casualty and business interruption insurance, and the extent of insurance recovery for these expenses continues to be reviewed by its outside advisors. As of March 31, 2008, no receivables for insurance recoveries have been recorded by the Company.

37

(iii) Operating income included special litigation and other related professional fees of $21.6 million pretax ($13.0 million aftertax) for litigation-related professional expenses primarily in connection with the Company’s lawsuit against United, certain other large customer disputes, the administrative subpoenas from the United States Attorney’s Office, District of Massachusetts, the purported class and derivative actions, the investigation by the federal government and certain states relating to drug substitutions, and the Company’s response to subpoenas it received relating to other legal proceedings to which the Company is not a party. With respect to these proceedings to which the Company is a party, see further discussion at the “Commitments and Contingencies” note of the Notes to Consolidated Financial Statements, and the “Legal Proceedings” section at Part II, Item 1 of this Filing.

The three months ended March 31, 2007 included the following charges, which primarily impacted the Pharmacy Services segment. Management believes that these special items are either infrequent occurrences or otherwise not related to Omnicare’s ordinary course of business:

(i)Operating income included restructuring and other related charges of approximately $9.2 million pretax ($5.7 million aftertax), relating to the implementation of the “Omnicare Full Potential” Plan, a major initiative primarily designed to re-engineer the pharmacy operating model to increase efficiency and enhance customer growth. See further discussion at the “Restructuring and Other Related Charges” note of the Notes to Consolidated Financial Statements and the “Restructuring and Other Related Charges” section of this MD&A.

(ii)During the three months ended March 31, 2007, special charges relating to the aforementioned Heartland Matters of $5.8 million pretax (approximately $4.3 million and $1.5 million was recorded in the cost of sales and operating expense sections of the Consolidated Statements of Income, respectively) ($3.6 million aftertax) were recorded associated with these increased costs. As previously disclosed, the Company maintains product recall, property and casualty, and business interruption insurance, and the extent of insurance recovery for these expenses continues to be reviewed by its outside advisors. As of March 31, 2007, no receivables for insurance recoveries were recorded by the Company.

(iii)Operating income included a special litigation charge of $6.9 million pretax ($4.3 million aftertax) for litigation-related professional expenses primarily in connection with the administrative subpoenas from the United States Attorney’s Office, District of Massachusetts, the purported class and derivative actions, the Company’s lawsuit against United, and the investigation by the federal government and certain states relating to drug substitutions. See further discussion at the “Commitments and Contingencies” note of the Notes to Consolidated Financial Statements, and the “Legal Proceedings” section at Part II, Item 1 of this Filing.

38

Pharmacy Services Segment
	Three months ended March 31,
	2008		2007
Net sales	$	1,509,806	$	1,529,643
Operating income	$	109,235	$	135,590

Three Months Ended March 31, 2008 vs. 2007

Omnicare’s Pharmacy Services segment recorded sales of $1,509.8 million for the three months ended March 31, 2008, down from the 2007 amount of $1,529.6 million by $19.8 million, or 1.3% . At March 31, 2008, Omnicare served long-term care facilities as well as chronic care and other settings comprising approximately 1,446,000 beds, including approximately 69,000 patients served by the patient assistance programs of its specialty pharmacy business that had not previously been included. The comparable number at December 31, 2007 was 1,449,000 (including 57,000 specialty pharmacy patients) and 1,468,000 (including 68,000 specialty pharmacy patients) at March 31, 2007. Pharmacy Services sales were unfavorably impacted by a lower number of beds served, as well as the impact of a bed mix shift toward assisted living, which typically has lower penetration rates than skilled nursing facilities, the increased availability and utilization of generic drugs, reductions in reimbursement and/or utilization of certain drugs as well as competitive pricing issues, and lower revenues reported from copays and rejects under Part D as well as from certain matters currently in litigation. Partially offsetting these factors was the favorable impact of drug price inflation, acquisitions and increased drug utilization. While the Company is focused on reducing its costs to mitigate the impact of drug pricing and reimbursement issues, there can be no assurance that such issues or other pricing and reimbursement pressures will not adversely impact the Pharmacy Services segment.

Operating income of the Pharmacy Services segment was $109.2 million in the first quarter of 2008, a $26.4 million decrease as compared with the $135.6 million earned in the comparable period of 2007. As a percentage of the segment’s sales, operating income was 7.2% for the first quarter of 2008, compared with 8.9% in 2007. The 2008 quarter was unfavorably impacted primarily by the operating income effect of the aforementioned reductions in sales as well as the year-over-year impact of the previously mentioned special items. Operating income in 2008 was favorably impacted largely by the increased availability and utilization of higher margin generic drugs, drug price inflation, and purchasing improvements, as well as the Company’s continued integration of prior-period acquisitions and productivity enhancements.

The Company derives a significant portion of its revenues directly or indirectly from government-sponsored programs, principally the federal Medicare program and to a lesser extent state Medicaid programs. As part of ongoing operations, the Company and its customers are subject to regulatory changes in the level of reimbursement received from the Medicare and Medicaid programs. Since 1997, Congress has passed a number of federal laws that have effected major changes in the healthcare system and payments to certain providers.

39

The Balanced Budget Act of 1997 (the “BBA”) mandated a prospective payment system (“PPS”) for Medicare-eligible residents of skilled nursing facilities (“SNFs”). Under PPS, Medicare pays SNFs a fixed fee per patient per day based upon the acuity level of the resident, covering substantially all items and services furnished during a Medicare-covered stay, including pharmacy services. PPS initially resulted in a significant reduction of reimbursement to SNFs. Congress subsequently sought to restore some of the reductions in reimbursement resulting from PPS. One provision gave SNFs a temporary rate increase for certain specific high-acuity patients beginning April 1, 2000, and ending when the Centers for Medicare & Medicaid Services (“CMS”) implemented a refined patient classification system under PPS. For several years, CMS did not implement such refinements, thus continuing the additional rate increase for certain high-acuity patients through federal fiscal year 2005.

On August 4, 2005, CMS issued its final SNF PPS rule for fiscal year 2006. Under the rule, CMS added nine patient classification categories to the PPS patient classification system, thus triggering the expiration of the high-acuity payments add-ons. However, CMS estimated that the rule would have a slightly positive financial impact on SNFs in fiscal year 2006 because the $1.02 billion reduction from the expiration of the add-on payments would be more than offset by a $510 million increase in the nursing case-mix weight for all of the resource utilization group categories and a $530 million increase associated with various updates to the payment rates (including updates to the wage and market basket indexes), resulting in a $20 million overall increase in payments for fiscal year 2006. The new patient classification refinements became effective on January 1, 2006, and the market basket increase became effective October 1, 2005. On July 31, 2006, CMS issued the update to the SNF PPS rates for fiscal year 2007. Effective October 1, 2006, SNFs receive the full 3.1 percent market basket increase to rates, increasing payments to SNFs by approximately $560 million for fiscal year 2007. On August 3, 2007, CMS published its final SNF PPS update for fiscal year 2008. Effective October 1, 2007, SNFs receive a 3.3 percent market basket increase, which increases Medicare payments to SNFs by approximately $690 million in fiscal year 2008. The final rule also includes several policy and payment provisions, including rebasing the market basket, which currently reflects data from fiscal 1997, to a base year of fiscal year 2004; revisions to the calculation of the SNF market basket (including revising the pharmacy component); changing the threshold for forecast error adjustments from the current 0.25 percentage point to 0.5 percentage point; and continuing a special adjustment made to cover the additional services required by nursing home residents with HIV/AIDS. On May 1, 2008, CMS released its proposed SNF PPS update for fiscal year 2009. Among other things, the proposed rule would recalibrate case mix weights, resulting in an overall 3.3 percent reduction in Medicare payments. Most of the decrease would be offset by a 3.1 percent market basket increase, but if the rule were adopted as proposed, SNFs would experience a net reduction in Medicare payments of $60 million, or approximately 0.3 percent. The rule is subject to public comment until June 30, 2008, and a final rule will be issued this summer. While the fiscal year 2007 and 2008 SNF PPS rates do not decrease payments to SNFs, the potential loss of revenues associated with any proposed changes in SNF payments could, in the future, have an adverse effect on the financial condition of the Company’s SNF clients which could, in turn, adversely affect the timing or level of their payments to Omnicare.

Moreover, on February 8, 2006, the President signed into law the Deficit Reduction Act (“DRA”), which will reduce net Medicare and Medicaid spending by approximately $11 billion

40

over five years. Among other things, the legislation reduces Medicare SNF bad debt payments by 30 percent for those individuals who are not dually eligible for Medicare and Medicaid. This provision is expected to reduce payments to SNFs by $100 million over five years (fiscal years 2006-2010). On February 4, 2008, the Bush Administration released its fiscal year 2009 budget proposal, which includes legislative and administrative proposals that would reduce Medicare spending by approximately $12.2 billion in fiscal year 2009 and $178 billion over five years. Among other things, the budget would provide no annual update for SNFs in 2009 through 2011 and a -0.65 percent adjustment to the update annually thereafter. In addition, the budget would apply a “sequester” of -0.4 percent to all Medicare provider payments when general fund contributions exceed 45 percent of program spending. The sequester order would increase each year by -0.4 percent until general revenue funding is brought back to 45 percent. The budget also would move toward site-neutral post-hospital payments to limit perceived inappropriate incentives for five conditions commonly treated in both SNFs and inpatient rehabilitation facilities. The Administration also proposes to achieve savings by issuing regulations to adjust for case mix distribution in the SNF payment system. CMS included this provision in its proposed SNF prospective payment system update for fiscal year 2009, released May 1, 2008. CMS estimates that the recalibration would result in an overall 3.3 percent reduction in Medicare payments in fiscal year 2009, although the proposed rule would partially offset the case mix recalibration payment decrease with a 3.1 percent market basket increase. In addition, the budget proposal would eliminate all bad debt reimbursements for unpaid beneficiary cost-sharing over four years. Many provisions of the proposed Bush budget would require Congressional action to implement. Separately, on August 1, 2007, the House of Representatives approved H.R. 3162, the Children’s Health and Medicare Protection Act of 2007, that included a number of Medicare policy changes, including a freeze in fiscal year 2008 SNF PPS rates at fiscal year 2007 levels. Note that while the version of the bill that ultimately passed Congress did not include Medicare provisions impacting SNF reimbursement, Congress may yet consider these and other proposals in the future that would further restrict Medicare funding for SNFs.

In December 2003, Congress enacted the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (“MMA”), which included a major expansion of the Medicare prescription drug benefit under a new Medicare Part D.

Under the Medicare Part D prescription drug benefit, Medicare beneficiaries may enroll in prescription drug plans offered by private entities (or in a “fallback” plan offered on behalf of the government through a contractor, to the extent private entities fail to offer a plan in a given area), which provide coverage of outpatient prescription drugs (collectively, “Part D Plans”). Part D Plans include both plans providing the drug benefit on a stand-alone basis and Medicare Advantage plans providing drug coverage as a supplement to an existing medical benefit under that Medicare Advantage plan, most commonly a health maintenance organization plan. Medicare beneficiaries generally have to pay a premium to enroll in a Part D Plan, with the premium amount varying from plan to plan, although CMS provides various federal subsidies to Part D Plans to reduce the cost to beneficiaries. Effective January 1, 2006, Medicare beneficiaries who are also entitled to benefits under a state Medicaid program (so-called “dual eligibles”) have their prescription drug costs covered by the new Medicare drug benefit. Many nursing home residents Omnicare serves are dual eligibles, whose drug costs were previously

41

covered by state Medicaid programs. In 2007, approximately 42% of Omnicare’s revenue was derived from beneficiaries covered under the federal Medicare Part D program.

CMS provides premium and cost-sharing subsidies to Part D Plans with respect to dual eligible residents of nursing homes. Such dual eligibles are not required to pay a premium for enrollment in a Part D Plan, so long as the premium for the Part D Plan in which they are enrolled is at or below the premium subsidy, nor are they required to meet deductibles or pay copayment amounts. Further, all dual eligibles who do not affirmatively enroll in a Part D Plan are automatically enrolled into a Prescription Drug Plan (“PDP”) by CMS on a random basis from among those PDPs meeting CMS criteria for low-income premiums in the PDP region. As is the case for any nursing home beneficiary, such dual eligible beneficiaries may select a different Part D Plan at any time through the Part D enrollment process. In sum, dual eligible residents of nursing homes are entitled to have their prescription drug costs covered by a Part D Plan, provided that the prescription drugs which they are taking are either on the Part D Plan’s formulary, or an exception to the plan’s formulary is granted. CMS requires the formularies of Part D Plans to include the types of drugs most commonly needed by Medicare beneficiaries and to offer an exceptions process to provide coverage for medically necessary drugs.

Pursuant to the final Part D rule, effective January 1, 2006, the Company obtains reimbursement for drugs it provides to enrollees of a given Part D Plan in accordance with the terms of agreements negotiated between it and that Part D Plan. The Company has entered into such agreements with nearly all Part D Plan sponsors under which it will provide drugs and associated services to their enrollees. The Company continues to have ongoing discussions with Part D Plans in the ordinary course. Moreover, the Company may, as appropriate, renegotiate agreements. Further, the proportion of the Company’s Part D business serviced under specific agreements may change over time. Consequently, there can be no assurance that the reimbursement terms which currently apply to the Company’s Part D business will not change. Moreover, as expected in the transition to a new program of this magnitude, certain administrative and payment issues have arisen, resulting in higher operating expenses, as well as outstanding gross accounts receivable (net of allowances for contractual adjustments, and prior to any allowance for doubtful accounts) for copays and rejected claims. As of March 31, 2008, copays outstanding from Part D Plans were approximately $43 million, of which approximately $19 million relates to 2006. Additionally, as of March 31, 2008, Part D rejected claims outstanding from Part D Plans for the 2006 transitional year were approximately $21 million. Participants in the long-term care pharmacy industry continue to address these issues with CMS and the Part D Plans and attempt to develop solutions. The Company is also pursuing legal actions against certain Part D payors to collect outstanding copays. However, until all administrative and payment issues are fully resolved, there can be no assurance that the impact of the Part D drug benefit on the Company’s results of operations, financial position or cash flows will not change based on the outcome of any unforeseen future developments.

The MMA does not change the manner in which Medicare pays for drugs for Medicare beneficiaries covered under a Medicare Part A stay. The Company continues to receive reimbursement for drugs provided to such residents from the SNFs, in accordance with the terms of the agreements it has negotiated with each SNF. The Company also continues to receive reimbursement from the state Medicaid programs, albeit to a greatly reduced extent, for those

42

Medicaid beneficiaries not eligible for the Part D program, including those under age 65, and for certain drugs specifically excluded from Medicare Part D.

CMS has issued subregulatory guidance on many aspects of the final Part D rule, including the provision of pharmaceutical services to long-term care residents. CMS has also expressed some concerns about pharmacies’ receipt of discounts, rebates and other price concessions from drug manufacturers. Specifically, in a finalized “Call Letter” for the 2007 calendar year, CMS indicated that beginning in 2007, Part D sponsors must have policies and systems in place, as part of their drug utilization management programs, to protect beneficiaries and reduce costs when long-term care pharmacies are subject to incentives to move market share through access/performance rebates from drug manufacturers. For the purposes of managing and monitoring drug utilization, especially where such rebates exist, CMS instructs Part D Plan sponsors to require pharmacies to disclose to the Part D Plan sponsor any discounts, rebates and other direct or indirect remuneration designed to directly or indirectly influence or impact utilization of Part D drugs. CMS stated that Plan sponsors should provide assurances that such information will remain confidential. CMS has issued subregulatory guidelines specifying the information that CMS is requiring from Plan sponsors with respect to rebates paid to long-term care pharmacies. CMS has also issued reporting requirements for 2008 which, among other things, require disclosure of rebates provided to long-term care pharmacies at a more detailed level. The Company has agreed with various Plan sponsors and their agents with respect to the format, terms and conditions for providing such information and the Company intends to continue to work with other sponsors with respect to providing such information.

CMS continues to issue guidance on and make revisions to the Part D program. The Company is continuing to monitor issues relating to implementation of the Part D benefit, and until further agency guidance is known and until all administrative and payment issues associated with the transition to this massive program are fully resolved, there can be no assurance that the impact of the final rule or the outcome of other potential developments relating to its implementation on our business, results of operations, financial position or cash flows will not change based on the outcome of any unforeseen future developments.

The MMA also changed the Medicare payment methodology and conditions for coverage of certain items of durable medical equipment prosthetics, orthotics, and supplies (“DMEPOS”) under Medicare Part B. Approximately 1% of the Company’s revenue is derived from beneficiaries covered under Medicare Part B. The changes include a temporary freeze in annual increases in payments for durable medical equipment from 2004 through 2008, new clinical conditions for payment, quality standards (applied by CMS-approved accrediting organizations), and competitive bidding requirements. On April 10, 2007, CMS issued a final rule establishing the Medicare competitive bidding program. Only suppliers that are winning bidders will be eligible to provide competitively-bid items to Medicare beneficiaries in the selected areas. Enteral nutrients, equipment and supplies and oxygen equipment and supplies are among the 10 categories of DMEPOS included in the first round of the competitive bidding program for 10 geographic areas beginning July 1, 2008 (a delay from the previously-announced implementation date of April 1, 2008). The Company submitted bids for nine competitive bidding areas. CMS began announcing awards in March 2008. On March 20, 2008, the Company received form letters from

43

Palmetto GBA, the company that CMS has contracted with as the Competitive Bidding Implementation Contractor, stating that it was unable to accept the bids due to the alleged submission of insufficient financial documentation along with its bids. However, the Company, in consultation with its outside advisors, believes that in fact it had included the required financial documentation. As a result, CMS is reassessing the Company's bid denials. Further, many other suppliers had bids rejected due to alleged deficiencies in their bid submissions. Industry trade reports have indicated that 63 percent of all bids in round one were rejected. On May 6, 2008, a congressional committee held a hearing due to concerns that some suppliers were improperly excluded from the bidding process. It is uncertain at this time whether the Company's bids for the first round of competitive bidding will be accepted. In the meantime, CMS has also announced the 70 locations in which the second round of competitive bidding will be conducted later in 2008. The expanded program will apply to eight product categories, again including oxygen supplies and equipment and enteral nutrients, equipment and supplies. Bid prices will take effect sometime in 2009. Further, all existing DMEPOS suppliers will need to submit proof of accreditation by a deemed accreditation organization by September 30, 2009, although suppliers in the competitive bidding regions and new suppliers are subject to earlier accreditation deadlines. The Company intends to comply with all accreditation requirements for DMEPOS suppliers by the applicable deadline.

With respect to Medicaid, the BBA repealed the “Boren Amendment” federal payment standard for Medicaid payments to nursing facilities, giving states greater latitude in setting payment rates for such facilities. The law also granted states greater flexibility to establish Medicaid managed care programs without the need to obtain a federal waiver. Although these waiver programs generally exempt institutional care, including nursing facilities and institutional pharmacy services, some states do use managed care principles in their long-term care programs. Likewise, the DRA includes several changes to the Medicaid program designed to rein in program spending. These include, among others, strengthening the Medicaid asset transfer restrictions for persons seeking to qualify for Medicaid long-term care coverage, which could, due to the timing of the penalty period, increase facilities’ exposure to uncompensated care. This provision is expected to reduce Medicaid spending by an estimated $2.4 billion over five years. The law also gives states greater flexibility to expand access to home and community based services by allowing states to provide these services as an optional benefit without undergoing the waiver approval process, and includes a new demonstration to encourage states to provide long-term care services in a community setting to individuals who currently receive Medicaid services in nursing homes. Together, these provisions could increase state funding for home and community-based services, while prompting states to cut funding for nursing facilities. No assurances can be given that state Medicaid programs ultimately will not change the reimbursement system for long-term care or pharmacy services in a way that adversely impacts the Company.

The DRA also changed the so-called federal upper limit payment rules for multiple source prescription drugs covered under Medicaid. Like the current upper limit, it only applies to drug ingredient costs and does not include dispensing fees, which will continue to be determined by the states. First, the DRA redefined a multiple source drug subject to the upper limit rules to be a covered outpatient drug that has at least one other drug product that is therapeutically equivalent. Thus, the federal upper limit is triggered when there are two or more therapeutic equivalents, instead of three or more as was previously the case. Second, effective January 1, 2007, the DRA

44

changed the federal upper payment limit from 150 percent of the lowest published price for a drug (which is usually the average wholesale price) to 250 percent of the lowest average manufacturer price (“AMP”). Congress expected these DRA provisions to reduce federal and state Medicaid spending by $8.4 billion over five years. On July 17, 2007, CMS issued a final rule with comment period to implement changes to the upper limit rules. Among other things, the final rule: establishes a new federal upper limit calculation for multiple source drugs that is based on 250 percent of the lowest AMP in a drug class; promotes transparency in drug pricing by requiring CMS to post AMP amounts on its web site; and establishes a uniform definition for AMP. Additionally, the final rule provides that sales of drugs to long-term care pharmacies for supply to nursing homes and assisted living facilities (as well as associated discounts, rebates or other price concessions) are not to be taken into account in determining AMP where such sales can be identified with adequate documentation, and that any AMPs which are not at least 40% of the next highest AMP will not be taken into account in determining the upper limit amount (the so-called “outlier” test). However, on December 19, 2007, the United States District Court for the District of Columbia issued a preliminary injunction that enjoins CMS from implementing provisions of the July 17, 2007 rule to the extent that it affects Medicaid reimbursement rates for retail pharmacies under the Medicaid program. The order also enjoins CMS from posting AMP data on a public website or disclosing it to states. As a result of this preliminary injunction, CMS did not post AMPs or new upper limit prices in late December 2007 based upon the July 17, 2007 final rule despite its earlier planned timetable, and the schedule for states to implement the new upper limits will be delayed until further notice. Separately, on March 14, 2008, CMS published an interim final rule with comment period revising the Medicaid rebate definition of multiple source drug set forth in the July 17, 2007 final rule. In short, the effect of the rule will be that federal upper limits apply in all states unless the state finds that a particular generic drug is not available within that state. While the rule’s effective date is April 14, 2008, it is subject to public comment. CMS also notes that the regulation is subject to the injunction by the United States District Court for the District of Columbia to the extent that it may affect Medicaid reimbursement rates for pharmacies. With the advent of Medicare Part D, the Company’s revenues from state Medicaid programs are substantially lower than has been the case previously. However, some of the Company’s agreements with Part D Plans and other payors have incorporated the Medicaid upper limit rules into the pricing mechanisms for prescription drugs. Until the new upper limit amounts are published by CMS, the Company cannot predict the impact of the final rule on the Company’s business. There can be no assurance, however, that the changes under the DRA or other efforts by payors to limit reimbursement for certain drugs will not have an adverse impact on the Company’s business.

President Bush’s fiscal year 2009 budget proposal includes a series of proposals impacting Medicaid, including legislative and administrative changes that would reduce Medicaid payments by more than $18 billion over five years. Among other things, the proposed budget would further reduce the federal upper limit reimbursement for multiple source drugs to 150 percent of the AMP and replace the “best price” component of the Medicaid drug rebate formula with a budget-neutral flat rebate. Many of the proposed policy changes would require Congressional approval to implement. While the Company has endeavored to adjust to these types of funding pressures in the past, there can be no assurance that these or future changes in Medicaid payments to nursing facilities, pharmacies, or managed care systems, or their potential

45

impact on payments under agreements with Part D Plans, will not have an adverse impact on its business.

Two recent actions at the federal level could impact Medicaid payments to nursing facilities. The Tax Relief and Health Care Act of 2006 modified several Medicaid policies including, among other things, reducing the limit on Medicaid provider taxes from 6 percent to 5.5 percent from January 1, 2008 through September 30, 2011. The Bush Administration had been expected to issue regulations calling for deeper cuts in this funding. On February 22, 2008, CMS published a final rule that implements this legislation, and makes other clarifications to the standards for determining the permissibility of provider tax arrangements. Second, on January 18, 2007, CMS published a proposed rule designed to ensure that Medicaid payments to governmentally-operated nursing facilities and certain other health care providers are based on actual costs and that state financing arrangements are consistent with the Medicaid statute. CMS estimates that the rule, if finalized, would save $120 million during the first year and $3.87 billion over five years. On May 29, 2007, CMS published a final rule to implement this provision, but Congress blocked the rule for one year in an emergency fiscal year 2007 spending bill, H.R. 2206. Legislation is under consideration in Congress that, if enacted, would further extend the moratorium.

On October 4, 2006, the plaintiffs in New England Carpenters Health Benefits Fund et al. v. First DataBank, Inc. and McKesson Corporation, CA No. 1:05-CV-11148-PBS (United District Court for the District of Massachusetts) and defendant First DataBank, Inc. (“First DataBank”) entered into a settlement agreement relating to First DataBank’s publication of average wholesale price (“AWP”). AWP is a pricing benchmark that is widely used to calculate a portion of the reimbursement payable to pharmacy providers for the drugs and biologicals they provide, including under State Medicaid programs, Medicare Part D Plans and certain of the Company’s contracts with long-term care facilities. The settlement agreement would require First DataBank to cease publishing AWP two years after the settlement becomes effective unless a competitor of First DataBank is then publishing AWP, and would require that First DataBank modify the manner in which it calculates AWP until First DataBank ceases publishing same. On June 6, 2007 the Court granted preliminary approval to an amended settlement agreement. Although the settlement agreement is yet subject to final approval of the court, the Company is evaluating the potential impact of the settlement in the context of certain of the contracts that it has with various payors and the actions that may be taken, if necessary, to offset or otherwise mitigate such impact. In addition, the government and private health insurance programs could discontinue or modify the use of AWP or otherwise implement payment methods that reduce the reimbursement for drugs and biologicals. There can be no assurance, however, that the First DataBank settlement, if approved, or actions, if any, by the government or private health insurance programs relating to AWP would not have an adverse impact on the Company’s reimbursement for drugs and biologicals and have implications for the use of AWP as a benchmark from which pricing in the pharmaceutical industry is negotiated, which could adversely affect the Company. In a related case, District Council 37 Health and Security Plan v. Medi-Span, CA No. 1:07-CV-10988-PBS (United States District Court for the District of Massachusetts), in which Medi-Span is accused of misrepresenting pharmaceutical prices by relying on and publishing First Databank’s price list, the parties entered into a similar settlement agreement, and the Court granted preliminary approval of the agreement on June 21, 2007, and granted amended preliminary approval of the agreement on August 21, 2007. On January 22,

46

2008, the court held a hearing on a motion for final approval of the proposed settlements. The court heard various objections to the proposed settlements and indicated that it would not approve the settlement as proposed. The court asked the parties to report back to it by February 5, 2008 with respect to various of the issues raised, and whether the settlements might be revised and additional evidence might be introduced to address these issues. The parties filed amendments to the proposed settlements on March 19, 2008, and at a status hearing held that day, the Court asked the parties to further revise the amended settlements. The Company is monitoring these cases for further developments and evaluating potential implications and/or actions that may be required. If a revised settlement or other resolution of the cases is proposed, the Company will evaluate the potential impact of such settlement or other resolution on the Company at that time, including any adverse effect on the Company’s reimbursement for drugs and biologicals and any actions that may be taken to offset or otherwise mitigate such impact.

Longer term, funding for federal and state healthcare programs must consider the aging of the population and the growth in enrollees as eligibility is expanded; the escalation in drug costs owing to higher drug utilization among seniors and the introduction of new, more efficacious but also more expensive medications; the impact of the Medicare Part D program; and the long-term financing of the Medicare and Medicaid programs. Given competing national priorities, it remains difficult to predict the outcome and impact on the Company of any changes in healthcare policy relating to the future funding of the Medicare and Medicaid programs.

Demographic trends indicate that demand for long-term care will increase well into the middle of this century as the elderly population grows significantly. Moreover, those over 65 consume a disproportionately high level of healthcare services, including prescription drugs, when compared with the under-65 population. There is widespread consensus that appropriate pharmaceutical care is generally considered the most cost-effective form of treatment for the chronic ailments afflicting the elderly and also one that is able to improve the quality of life. These trends not only support long-term growth for the geriatric pharmaceutical industry but also containment of healthcare costs and the well-being of the nation’s growing elderly population.

In order to fund this growing demand, the Company anticipates that the government and the private sector will continue to review, assess and possibly alter healthcare delivery systems and payment methodologies. While it cannot at this time predict the ultimate effect of the Medicare Part D drug benefit or any further initiatives on Omnicare’s business, management believes that the Company’s expertise in geriatric pharmaceutical care and pharmaceutical cost management position Omnicare to help meet the challenges of today’s healthcare environment. Further, while volatility can occur from time to time in the contract research business owing to factors such as the success or failure of its clients’ compounds, the timing or budgetary constraints of its clients, or consolidation within our client base, new drug discovery remains an important priority of drug manufacturers. Drug manufacturers, in order to optimize their research and development efforts, will continue to turn to contract research organizations to assist them in accelerating drug research development and commercialization.

47

CRO Services Segment
	Three months ended March 31,
	2008		2007
Revenues	$	49,173	$	47,422
Operating income	$	2,668	$	730

Three Months Ended March 31, 2008 vs. 2007

Omnicare’s CRO Services segment recorded revenues of $49.2 million for the three months ended March 31, 2008, which increased by $1.8 million, or 3.7% from the $47.4 million recorded in the same prior-year period. In accordance with Emerging Issues Task Force (“EITF”) Issue No. 01-14, “Income Statement Characterization of Reimbursements Received for “Out-of-Pocket” Expenses Incurred” (“EITF No. 01-14”), the Company included $7.4 million and $7.3 million of reimbursable out-of-pockets in its CRO Services segment reported revenue and direct cost amounts for the three months ended March 31, 2008 and 2007, respectively. Revenues for 2008 were higher than in the same prior-year period primarily due to the commencement and ramp-up of projects that were awarded in 2007 and in the first quarter of 2008, exceeding project terminations and cancellations.

Operating income in the CRO Services segment was $2.7 million in the first quarter of 2008 compared with $0.7 million in 2007, an increase of $2.0 million. As a percentage of the segment’s revenue, operating income was 5.4% in the first quarter of 2008 compared with 1.5% in the same period of 2007. This increase is primarily attributable to the favorable impact of the increase in revenues discussed above and the favorable year-over-year impact of special items. Backlog at March 31, 2008 was $309.4 million, representing a decrease of $4.9 million from the December 31, 2007 backlog of $314.3 million, and an increase of $9.1 million from the March 31, 2007 backlog of $300.3 million.

Restructuring and Other Related Charges

Omnicare Full Potential Program

In 2006, the Company commenced the implementation of the “Omnicare Full Potential” Plan, a major initiative primarily designed to re-engineer the Company’s pharmacy operating model to increase efficiency and enhance customer growth. The Omnicare Full Potential Plan is expected to optimize resources across the entire organization by implementing best practices, including the realignment and right-sizing of functions, and a “hub-and-spoke” model whereby certain key administrative and production functions will be transferred to regional support centers (“hubs”) specifically designed and managed to perform these tasks, with local pharmacies (“spokes”) focusing on time-sensitive services and customer-facing processes.

48

This program is expected to be completed over a multi-year period and is estimated to generate pretax savings in the range of $100 million to $120 million annually upon completion of the initiative. It is anticipated that approximately one-half of these savings will be realized in cost of sales, with the remainder being realized in operating expenses. The program is estimated to result in total pretax restructuring and other related charges of approximately $93 million over this implementation period. The charges primarily include severance pay, employment agreement buy-outs, excess lease costs and professional fees, as well as other related costs. The Company recorded restructuring and other related charges for the Omnicare Full Potential Plan of approximately $6 million and $9 million pretax (approximately $4 million and $6 million aftertax) during the three months ended March 31, 2008 and 2007, respectively. The Omnicare Full Potential Plan initiatives required cumulative restructuring and other related charges of approximately $53 million before taxes through the first quarter of 2008. The remainder of the overall restructuring and other related charges will be recognized and disclosed prospectively, as various phases of the project are finalized and implemented. Incremental capital expenditures related to this program are expected to total approximately $45 million to $50 million over the implementation period. The Company estimates that the program has led to a reduction in force of approximately 1,200 positions as of March 31, 2008, associated primarily with its pharmacy operations. While the Company is working diligently to achieve the estimated savings as discussed above, there can be no assurances as to the ultimate outcome of the program, including the related timing thereof, due to the inherent risks associated with the implementation of a project of this magnitude and the related new technologies. Specifically, the potential inability to successfully mitigate implementation risks, including but not necessarily limited to, dependence on third-party suppliers and consultants for the timely delivery of technology as well as its performance at expected capacities, compliance with federal, state and local regulatory requirements, reliance on information technology and telecommunications support, timely completion of facility lease transactions and/or leasehold improvements, and the ability to obtain adequate staffing levels, individually or in the aggregate could affect the overall success of the program from a savings and/or timing standpoint.

See further discussion at the “Restructuring and Other Related Charges” note of the Notes to Consolidated Financial Statements.

2005 Program

In connection with the previously disclosed consolidation plans and other productivity initiatives to streamline pharmacy services (related, in part, to the NeighborCare, Inc. acquisition) and contract research organization operations, including maximizing workforce and operating asset utilization, and producing a more cost-efficient, operating infrastructure (the “2005 Program”), the Company had liabilities of $5.3 million at December 31, 2007, of which $0.5 million was utilized in the three months ended March 31, 2008. The remaining liabilities of $4.8 million at March 31, 2008 represent amounts not yet paid relating to actions taken in connection with the program (primarily lease payments) and will be settled as these matters are finalized.

49

Financial Condition, Liquidity and Capital Resources

Cash and cash equivalents and restricted cash at March 31, 2008 were $316.0 million compared with $277.6 million at December 31, 2007 (including restricted cash amounts of $14.8 million and $3.2 million, respectively).

The Company generated positive net cash flows from operating activities of $142.3 million during the three months ended March 31, 2008, compared with net cash flows from operating activities of $174.8 million during the three months ended March 31, 2007. Compared to the same prior-year period, cash flow from operating activities was unfavorably impacted primarily by the year-over-year trend in accounts payable on operating cash flows, partially offset largely by the favorable effect of the Company’s management of inventory levels in the first quarter of 2008.

Net cash used by investing activities was $60.0 million and $61.9 million for the three months ended March 31, 2008 and 2007, respectively. Acquisitions of businesses, primarily funded by operating cash flows, required outlays of $36.0 million (including amounts payable pursuant to acquisition agreements relating to pre-2008 acquisitions) in 2008. Acquisitions of businesses during the first three months of 2007 required $43.3 million of cash payments (including amounts payable pursuant to acquisition agreements relating to pre-2007 acquisitions) which were primarily funded by operating cash flows. Omnicare’s capital requirements, in addition to the payment of debt and dividends, are primarily comprised of its acquisition program and capital expenditures, largely relating to investments in the Company’s information technology systems and the implementation of the “Omnicare Full Potential” Plan.

Net cash used in financing activities was $58.1 million for the three months ended March 31, 2008 as compared to $66.2 million for the comparable prior-year period. During the first three months of 2008 and 2007, the Company paid down $50 million on the Company’s senior term A loan facility, maturing on July 28, 2010. Borrowings on the revolving credit facility totaled approximately $49 million during the first three months of 2008 and were completely repaid prior to the end of the period.

At March 31, 2008, there were no outstanding borrowings under the $800 million revolving credit facility, and $400 million in borrowings were outstanding under the senior term A loan facility due 2010. As of March 31, 2008, the Company had approximately $26.6 million outstanding relating to standby letters of credit, substantially all of which are subject to automatic annual renewals.

On February 14, 2008, the Company’s Board of Directors declared a quarterly cash dividend of 2.25 cents per common share for an indicated annual rate of 9 cents per common share for 2008, which is consistent with the annual dividends per share actually paid in 2007. Aggregate dividends of $2.7 million were paid during each of the three month periods ended March 31, 2008 and 2007.

50

On March 27, 2008, the Company announced that its Board of Directors has authorized a new program to repurchase, from time to time, shares of Omnicare's outstanding common stock having an aggregate value of up to $100 million, depending on market conditions and other factors. On March 31, 2008, Omnicare had approximately 121.6 million shares of common stock outstanding. These repurchases will be made in open market or privately negotiated transactions in compliance with Securities and Exchange Commission Rule 10b-18 and other applicable legal requirements. The manner, timing and amount of any purchases will be determined by the Company based on an evaluation of market conditions, stock price and other factors. The plan does not obligate Omnicare to acquire any particular amount of common stock, and it may be modified or suspended at any time at Omnicare's discretion.

There were no known material commitments and contingencies outstanding at March 31, 2008, other than the contractual obligations summarized in the “Disclosures About Aggregate Contractual Obligations and Off-Balance Sheet Arrangements” section below; certain acquisition-related payments potentially due in the future, including deferred payments, indemnification payments and payments originating from earnout and other provisions that may become payable; as well as the matters discussed in the “Commitments and Contingencies” note of the Notes to Consolidated Financial Statements, and the “Legal Proceedings” section at Part II, Item 1 of this Filing.

The Company believes that net cash flows from operating activities, credit facilities and other short- and long-term debt financings will be sufficient to satisfy its future working capital needs, acquisition contingency commitments, debt servicing, capital expenditures and other financing requirements for the foreseeable future. Additionally, the Company believes that external sources of financing are available, although no assurances can be given regarding the Company’s ability to obtain additional financing in the future.

51

Disclosures About Aggregate Contractual Obligations and Off-Balance Sheet Arrangements

Aggregate Contractual Obligations:

The following summarizes the Company’s aggregate contractual obligations as of March 31, 2008, and the effect such obligations are expected to have on the Company’s liquidity and cash flows in future periods (in thousands):

			Less Than 1
	Total		Year		1-3 Years		4-5 Years		After 5 Years
Debt obligations(a)	$	2,771,415	$	-	$	448,915	$	-	$	2,322,500
Capital lease obligations(a)		7,143		2,848		3,129		737		429
Operating lease obligations		161,389		44,464		58,325		26,729		31,871
Purchase obligations(b)		86,484		67,316		11,220		7,948		-
Other current obligations(c)		360,630		360,630		-		-		-
Other long-term obligations(d)		351,356		-		148,402		20,213		182,741
Subtotal		3,738,417		475,258		669,991		55,627		2,537,541
Future interest relating to debt
and capital lease obligations(e)		1,716,049		131,815		248,427		224,436		1,111,371
Total contractual cash obligations	$	5,454,466	$	607,073	$	918,418	$	280,063	$	3,648,912

(a)	The noted obligation amounts represent the principal portion of the associated debt obligations. Details of the Company’s outstanding debt instruments can be found in the “Debt” note of the Notes to Consolidated Financial Statements.
(b)	Purchase obligations primarily consist of open inventory purchase orders, as well as obligations for other goods and services, at period end.
(c)	Other current obligations primarily consist of accounts payable at period end.
(d)	Other long-term obligations are largely comprised of pension and excess benefit plan obligations, acquisition-related liabilities, as well as accruals relating to uncertain tax positions.
(e)	Represents estimated future pretax interest costs based on the stated fixed interest rate of the debt, or the variable interest rate in effect at period end for variable interest rate debt. The estimated future interest costs presented in this table do not include any amounts potentially payable associated with the contingent interest and interest reset provisions of the Company’s convertible debentures. To the extent that any debt would be paid off by Omnicare prior to the stated due date or refinanced, the estimated future interest costs would change accordingly. Further, these analyses do not consider the effects of potential changes in the Company’s credit rating.

As of March 31, 2008, the Company had approximately $26.6 million outstanding relating to standby letters of credit, substantially all of which are subject to automatic annual renewals.

52

Off-Balance Sheet Arrangements:

As of March 31, 2008, the Company had two unconsolidated entities, Omnicare Capital Trust I, a statutory trust formed by the Company (the “Old Trust”) and Omnicare Capital Trust II (the “New Trust”), which were established for the purpose of facilitating the offerings of the 4.00% Trust Preferred Income Equity Redeemable Securities due 2033 (the “Old Trust PIERS”) and the Series B 4.00% Trust Preferred Income Equity Redeemable Securities (the “New Trust PIERS”), respectively. For financial reporting purposes, the Old Trust and New Trust are treated as equity method investments of the Company. The Old Trust and New Trust are 100%-owned finance subsidiaries of the Company. The Company has fully and unconditionally guaranteed the securities of the Old Trust and New Trust. The Old 4.00% Debentures issued by the Company to the Old Trust and the New 4.00% Debentures issued by the Company to the New Trust in connection with the issuance of the Old Trust PIERS and the New Trust PIERS, respectively, are presented as a single line item in Omnicare’s Consolidated Balance Sheets and debt footnote disclosures. Additionally, the related disclosures concerning the Old Trust PIERS and the New Trust PIERS, the guarantees, and the Old 4.00% Debentures and New 4.00% Debentures are included in the “Debt” note of the Notes to Consolidated Financial Statements in Omnicare’s 2007 Annual Report. Omnicare records interest payable to the Old Trust and New Trust as interest expense in its Consolidated Statements of Income.

As of March 31, 2008, the Company had no other unconsolidated entities, or any financial partnerships, such as entities often referred to as structured finance or special purpose entities, which might have been established for the purpose of facilitating off-balance sheet arrangements.

Critical Accounting Policies

Allowance for Doubtful Accounts

Collection of accounts receivable from customers is the Company’s primary source of operating cash flow and is critical to Omnicare’s operating performance, cash flows and financial condition. Omnicare’s primary collection risk relates to facility, private pay and Part D customers. The Company provides a reserve for accounts receivable considered to be at increased risk of becoming uncollectible by establishing an allowance to reduce the carrying value of such receivables to their estimated net realizable value. Omnicare establishes this allowance for doubtful accounts using the specific identification approach, and considering such factors as historical collection experience (i.e., payment history and credit losses) and creditworthiness, specifically identified credit risks, aging of accounts receivable by payor category, current and expected economic conditions and other relevant factors. Management reviews this allowance for doubtful accounts on an ongoing basis for appropriateness. Judgment is used to assess the collectability of account balances and the economic ability of customers to pay.

The Company computes and monitors its accounts receivable days sales outstanding (“DSO”), a non-GAAP measure, in order to evaluate the liquidity and collection patterns of its accounts receivable. DSO is calculated by averaging the beginning and end of quarter accounts receivable, less contractual allowances and the allowance for doubtful accounts, to derive

53

"average accounts receivable" and dividing average accounts receivable by the sales amount (excluding reimbursable out-of-pockets) for the related quarter. The resultant percentage is multiplied by 92 days to derive the DSO amount. Omnicare’s DSO approximated 81 daysat March 31, 2008, which was lower than the December 31, 2007 DSO of approximately 84 days, largely attributable to the Company’s late 2007 increase in its provision for doubtful accounts. As previously disclosed, the Company has experienced on-going administrative and payment issues associated with the Medicare Part D implementation, resulting in outstanding gross accounts receivable (net of allowances for contractual adjustments, and prior to any allowance for doubtful accounts) for copays and rejected claims. As of March 31, 2008, copays outstanding from Part D Plans were approximately $43 million, of which approximately $19 million relates to 2006. Additionally, as of March 31, 2008, Part D rejected claims outstanding from Part D Plans for the 2006 transitional year were approximately $21 million. Unfavorably impacting the overall DSO, as well as the recent increases in the 181 days and over past due accounts receivable balance, is the aging in accounts receivable relating to several of the Company’s larger nursing home chain customers, and the continued aging of copays and rejected claims. On July 11, 2007, the Company commenced legal action against a group of its customers for, among other things, the collection of past-due receivables that are owed to the Company. Specifically, approximately $87 million (excluding interest and prior to any allowance for doubtful accounts) is owed to the Company by this group of customers as of March 31, 2008, of which approximately $79 million is past due based on applicable payment terms (a significant portion of which is not reserved). The $87 million represents approximately 5 days of the overall DSO at March 31, 2008. Until all administrative and payment issues relating to the Part D Drug Benefit as well as the aforementioned legal action against a group of Omnicare’s customers are fully resolved, there can be no assurance that the impact of these matters on the Company’s results of operations, financial position or cash flows will not change based on the outcome of any unforeseen future developments.

The allowance for doubtful accounts as of March 31, 2008 was $348.6 million, compared with $334.1 million at December 31, 2007. The allowance for doubtful accounts represented 20.4% and 19.5% of gross receivables (net of contractual allowances) as of March 31, 2008 and December 31, 2007, respectively. Unforeseen future developments could lead to changes in the Company’s provision for doubtful accounts levels and future allowance for doubtful accounts percentages, which could materially impact the overall financial results, financial position or cash flows of the Company. For example, a one percentage point increase in the allowance for doubtful accounts as a percentage of gross receivables (net of allowances for contractual adjustments, and prior to allowances for doubtful accounts) as of March 31, 2008 would result in an increase to the provision for doubtful accounts and related allowance for doubtful accounts on the balance sheet of approximately $17.1 million pretax.

The following table is an aging of the Company’s March 31, 2008 and December 31, 2007 gross accounts receivable (net of allowances for contractual adjustments, and prior to allowances for doubtful accounts), aged based on payment terms and categorized based on the four primary overall types of accounts receivable characteristics (in thousands):

54

			March 31, 2008
	Current and		181 Days and
	0-180 Days		Over
	Past Due		Past Due		Total
Medicare (Part D and Part B), Medicaid
and Third-Party payors	$	382,209	$	185,582	$	567,791
Facility payors		514,057		360,441		874,498
Private Pay payors		116,028		129,221		245,249
CRO		18,786		-		18,786
Total gross accounts receivable
(net of contractual allowance adjustments)	$	1,031,080	$	675,244	$	1,706,324
			December 31, 2007
	Current and		181 Days and
	0-180 Days		Over
	Past Due		Past Due		Total
Medicare (Part D and Part B), Medicaid
and Third-Party payors	$	390,663	$	167,116	$	557,779
Facility payors		527,879		347,551		875,430
Private Pay payors		126,480		124,958		251,438
CRO		25,702		-		25,702
Total gross accounts receivable
(net of contractual allowance adjustments)	$	1,070,724	$	639,625	$	1,710,349

Fair Value

On January 1, 2008, the Company partially adopted the provisions of Statement of Financial Accounting Standards (“SFAS”) No. 157, “Fair Value Measurements” (“SFAS 157”). SFAS 157 defines a hierarchy which prioritizes the inputs in fair value measurements. “Level 1” measurements are measurements using quoted prices in active markets for identical assets or liabilities. “Level 2” measurements use significant other observable inputs. “Level 3” measurements are measurements using significant unobservable inputs which require a company to develop its own assumptions. In recording the fair value of assets and liabilities, companies must use the most reliable measurement available. The impact to the Company’s consolidated results of operations, financial position and cash flows upon partial adoption of SFAS 157 was not material. The Company elected to partially defer adoption of SFAS 157 related to goodwill and indefinite-lived intangible assets in accordance with Financial Accounting Standards Board (“FASB”) Staff Position 157-2.

See further discussion at the “Fair Value” note of the Notes to Consolidated Financial Statements.

55

Legal Contingencies

The status of certain legal proceedings has been updated at the “Commitments and Contingencies” note of the Notes to Consolidated Financial Statements, and the “Legal Proceedings” section at Part II, Item 1 of this Filing.

Recently Issued Accounting Standards

Information pertaining to recently issued accounting standards is further discussed at the “Recently Issued Accounting Standards” section of the “Interim Financial Data, Description of Business and Summary of Significant Accounting Policies” note of the Notes to Consolidated Financial Statements of this Filing.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information

In addition to historical information, this report contains certain statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, all statements regarding the intent, belief or current expectations regarding the matters discussed or incorporated by reference in this document (including statements as to “beliefs,” “expectations,” “anticipations,” “intentions” or similar words) and all statements which are not statements of historical fact. Such forward-looking statements, together with other statements that are not historical, are based on management’s current expectations and involve known and unknown risks, uncertainties, contingencies and other factors that could cause results, performance or achievements to differ materially from those stated. The most significant of these risks and uncertainties are described in the Company’s Form 10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange Commission and include, but are not limited to: overall economic, financial, political and business conditions; trends in the long-term healthcare, pharmaceutical and contract research industries; the ability to attract new clients and service contracts and retain existing clients and service contracts; the ability to consummate pending acquisitions; trends for the continued growth of the Company’s businesses; trends in drug pricing; delays and reductions in reimbursement by the government and other payors to customers and to the Company; the overall financial condition of the Company’s customers and the ability of the Company to assess and react to such financial condition of its customers; the ability of vendors and business partners to continue to provide products and services to the Company; the continued successful integration of acquired companies; the continued availability of suitable acquisition candidates; the ability to attract and retain needed management; competition for qualified staff in the healthcare industry; the demand for the Company’s products and services; variations in costs or expenses; the ability to implement productivity, consolidation and cost reduction efforts and to realize anticipated benefits; the ability of clinical research projects to produce revenues in future periods; the potential impact of legislation, government regulations, and other government action and/or executive orders, including those relating to Medicare Part D, including its implementing regulations and any subregulatory guidance, reimbursement and drug pricing policies and changes in the interpretation and application of such policies; government budgetary pressures and shifting priorities; federal and

56

state budget shortfalls; efforts by payors to control costs; changes to or termination of the Company’s contracts with Medicare Part D plan sponsors or to the proportion of the Company’s Part D business covered by specific contracts; the outcome of litigation; potential liability for losses not covered by, or in excess of, insurance; the impact of differences in actuarial assumptions and estimates as compared to eventual outcomes; events or circumstances which result in an impairment of assets, including but not limited to, goodwill; market conditions; the outcome of audit, compliance, administrative, regulatory, or investigatory reviews; volatility in the market for the Company’s stock and in the financial markets generally; access to adequate capital and financing; changes in international economic and political conditions and currency fluctuations between the U.S. dollar and other currencies; changes in tax laws and regulations; changes in accounting rules and standards; and costs to comply with our Corporate Integrity Agreements. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, the Company’s actual results, performance or achievements could differ materially from those expressed in, or implied by, such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as otherwise required by law, the Company does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

ITEM 3 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Omnicare’s primary market risk exposure relates to variable interest rate risk through its borrowings. Accordingly, market risk loss is primarily defined as the potential loss in earnings due to higher interest rates on variable-rate debt of the Company. The modeling technique used by Omnicare for evaluating interest rate risk exposure involves performing sensitivity analysis on the variable-rate debt, assuming a change in interest rates of 100 basis-points. The Company’s debt obligations at March 31, 2008 include $400.0 million outstanding under the variable-rate Senior term A loan, due 2010, at an interest rate of 3.95% at March 31, 2008 (a 100 basis-point change in the interest rate would increase or decrease pretax interest expense by approximately $4.0 million per year); $48.9 million borrowed on a variable-rate term loan, due 2010, at an interest rate of 6.94% at March 31, 2008 (a 100 basis-point change in the interest rate would increase or decrease pretax interest expense by approximately $0.5 million per year); $250.0 million outstanding under its fixed-rate 6.125% Senior Notes, due 2013; $225.0 million outstanding under its fixed-rate 6.75% Senior Notes, due 2013; $525 million outstanding under its fixed-rate 6.875% Senior Notes, due 2015; $345.0 million outstanding under its fixed-rate 4.00% Convertible Debentures, due 2033; and $977.5 million outstanding under its fixed-rate 3.25% Convertible Debentures, due 2035 (with an optional repurchase right of holders on December 15, 2015). In connection with its offering of $250.0 million of 6.125% Senior Notes during 2003, the Company entered into a Swap Agreement on all $250.0 million of its aggregate principal amount of the 6.125% Senior Notes. Under the Swap Agreement, which hedges against exposure to long-term U.S. dollar interest rates, the Company receives a fixed rate of 6.125% and pays a floating rate based on LIBOR with a maturity of six months, plus a spread of 2.27%. The estimated LIBOR-based floating rate (including the 2.27% spread) was 4.90% at March 31, 2008 (a 100 basis-point change in the interest rate would increase or decrease pretax

57

interest expense by approximately $2.5 million per year). The Swap Agreement, which matches the terms of the 6.125% Senior Notes, is designated and accounted for as a fair value hedge. The Company is accounting for the Swap Agreement in accordance with SFAS No. 133, as amended, so changes in the fair value of the Swap Agreement are offset by changes in the recorded carrying value of the related 6.125% Senior Notes. The fair value of the Swap Agreement is recorded as a noncurrent asset or (liability), with an offsetting increase or (decrease), respectively, to the book carrying value of the related 6.125% Senior Notes, and amounted to approximately $0.4 million at the end of the 2008 first quarter. Additionally, at March 31, 2008, the fair value of Omnicare’s variable rate debt facilities approximated the carrying value, as the effective interest rates fluctuate with changes in market rates.

The fair value of the Company’s fixed-rate debt facilities is based on quoted market prices and is summarized as follows (in thousands):

Fair Value of Financial Instruments
	March 31, 2008				December 31, 2007
Financial Instrument:	Book Value		Market Value		Book Value		Market Value
6.125% senior subordinated notes, due 2013, gross	$	250,000	$	220,000	$	250,000	$	230,000
6.75% senior subordinated notes, due 2013		225,000		200,250		225,000		212,600
6.875% senior subordinated notes, due 2015		525,000		456,750		525,000		486,900
4.00% junior subordinated convertible
debentures, due 2033		345,000		206,831		345,000		246,700
3.25% convertible senior debentures, due 2035		977,500		630,488		977,500		703,800

Embedded in the Old Trust PIERS, the New Trust PIERS and the 3.25% Convertible Debentures are two derivative instruments, specifically, a contingent interest provision and a contingent conversion parity provision. In addition, the 3.25% Convertible Debentures include an interest reset provision. The embedded derivatives are periodically valued, and at period end, the values of the derivatives embedded in the Old Trust PIERS, the New Trust PIERS and the 3.25% Convertible Debentures were not material. However, the values are subject to change, based on market conditions, which could affect the Company’s future consolidated results of operations, financial position or cash flows.

The Company has operations and revenue that occur outside of the U.S. and transactions that are settled in currencies other than the U.S. dollar, exposing it to market risk related to changes in foreign currency exchange rates. However, the substantial portion of the Company’s operations and revenues and the substantial portion of the Company’s cash settlements are exchanged in U.S. dollars. Therefore, changes in foreign currency exchange rates do not represent a substantial market risk exposure to the Company.

The Company does not have any financial instruments held for trading purposes.

58

ITEM 4 - CONTROLS AND PROCEDURES

(a) Under applicable SEC regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the Company’s “disclosure controls and procedures,” which are defined generally as controls and other procedures of a reporting company designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Form 10-Q) is recorded, processed, accumulated and communicated to the Company’s management as appropriate to allow timely decisions regarding disclosure. Omnicare is an acquisitive company that continuously acquires and integrates new businesses. Throughout and following an acquisition, Omnicare focuses on analyzing the acquiree’s procedures and controls to determine their effectiveness and, where appropriate, implements changes to conform them to the Company’s disclosure controls and procedures. The Company’s Chief Executive Officer and Chief Financial Officer evaluated the Company’s disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q and concluded that they are effective.

(b) There were no changes in the Company’s internal control over financial reporting that occurred during the Company’s quarter ended March 31, 2008 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II - OTHER INFORMATION:

ITEM 1 - LEGAL PROCEEDINGS

On May 18, 2006, an antitrust and fraud action entitled Omnicare, Inc. v. UnitedHealth Group, Inc., et al., 2:06-cv-00103-WOB, was filed by the Company in the United States District Court for the Eastern District of Kentucky against UnitedHealth Group, Inc., PacifiCare Health Systems, Inc., and RxSolutions, Inc. d/b/a Prescription Solutions, asserting claims of violations of federal and state antitrust laws, civil conspiracy and common law fraud arising out of an alleged conspiracy by defendants to illegally and fraudulently coordinate their negotiations with the Company for Medicare Part D contracts as part of an effort to defraud the Company and fix prices. The complaint seeks, among other things, damages, injunctive relief and reformation of certain contracts. On June 5, 2006, the Company filed a first supplemental and amended complaint in which it asserted the identical claims. In an order dated November 9, 2006, a motion by defendants to transfer venue to the United States District Court for the Northern District of Illinois was granted, but a motion to dismiss the antitrust claims was denied without prejudice, with leave to refile in the transferee court. In the United States District Court for the Northern District of Illinois, the defendants renewed their motion to dismiss the Company’s antitrust claims on December 22, 2006, and on September 28, 2007 their motion was denied. On March 7, 2007, the Court entered a Minute Order setting a discovery schedule for the litigation. Fact discovery has been completed, and expert discovery is underway and expected to be completed by June 6, 2008. On April 18, 2008, the Court entered a Minute Order affirming its previous May 22, 2007 Minute Order that set a trial date of October 14, 2008.

59

The United States Attorney’s Office, District of Massachusetts, is conducting an investigation relating to the Company’s relationships with certain manufacturers and distributors of pharmaceutical products and certain customers, as well as with respect to contracts with certain companies acquired by the Company. Any action by the U.S. Attorney’s Office, District of Massachusetts, could result in civil or criminal proceedings against the Company. The Company believes that it has complied with all applicable laws and regulations with respect to these matters.

On February 2 and February 13, 2006, respectively, two substantially similar putative class action lawsuits, entitled Indiana State Dist. Council of Laborers & HOD Carriers Pension & Welfare Fund v. Omnicare, Inc., et al., No. 2:06cv26 (“HOD Carriers”), and Chi v. Omnicare, Inc., et al., No. 2:06cv31 (“Chi”), were filed against Omnicare and two of its officers in the United States District Court for the Eastern District of Kentucky purporting to assert claims for violation of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, and seeking, among other things, compensatory damages and injunctive relief. The complaints, which purported to be brought on behalf of all open-market purchasers of Omnicare common stock from August 3, 2005 through January 27, 2006, alleged that Omnicare had artificially inflated its earnings by engaging in improper generic drug substitution and that defendants had made false and misleading statements regarding the Company’s business and prospects. On April 3, 2006, plaintiffs in the HOD Carriers case formally moved for consolidation and the appointment of lead plaintiff and lead counsel pursuant to the Private Securities Litigation Reform Act of 1995. On May 22, 2006, that motion was granted, the cases were consolidated, and a lead plaintiff and lead counsel were appointed. On July 20, 2006, plaintiffs filed a consolidated amended complaint, adding a third officer as a defendant and new factual allegations primarily relating to revenue recognition, the valuation of receivables and the valuation of inventories. On October 31, 2006, plaintiffs moved for leave to file a second amended complaint, which was granted on January 26, 2007, on the condition that no further amendments would be permitted absent extraordinary circumstances. Plaintiffs thereafter filed their second amended complaint on January 29, 2007. The second amended complaint (i) expands the putative class to include all purchasers of Omnicare common stock from August 3, 2005 through July 27, 2006, (ii) names two members of the Company’s board of directors as additional defendants, (iii) adds a new plaintiff and a new claim for violation of Section 11 of the Securities Act of 1933 based on alleged false and misleading statements in the registration statement filed in connection with the Company’s December 2005 public offering, (iv) alleges that the Company failed to timely disclose its contractual dispute with UnitedHealth Group (see discussion of the UnitedHealth Group matter above), and (v) alleges that the Company failed to timely record certain special litigation reserves. Defendants filed a motion to dismiss the second amended complaint on March 12, 2007, claiming that plaintiffs had failed adequately to plead loss causation, scienter or any actionable misstatement or omission. That motion was fully briefed as of May 1, 2007. In response to certain arguments relating to the individual claims of the named plaintiffs that were raised in defendants’ pending motion to dismiss, plaintiffs filed a motion to add, or in the alternative, to intervene an additional named plaintiff, Alaska Electrical Pension Fund, on July 27, 2007. On October 12, 2007, the court issued an opinion and order dismissing the case and denying plaintiffs’ motion to add an additional named plaintiff. On November 9, 2007, plaintiffs filed a notice of appeal with the United States Court of Appeals for the Sixth Circuit and in a subsequent filing expressed an intention to appeal all aspects of the

60

lower court’s decision. The appellate court has issued a briefing schedule, plaintiffs obtained a 30-day extension of time to file their brief, and all briefs are now due by May 30, 2008. Oral argument on this appeal has not been scheduled.

On February 13, 2006, two substantially similar shareholder derivative actions, entitled Isak v. Gemunder, et al., Case No. 06-CI-390, and Fragnoli v. Hutton, et al., Case No. 06-CI-389, were filed in Kentucky State Circuit Court, Kenton Circuit, against the members of Omnicare’s board of directors, individually, purporting to assert claims for breach of fiduciary duty, abuse of control, gross mismanagement, waste of corporate assets and unjust enrichment arising out of the Company’s alleged violations of federal and state health care laws based upon the same purportedly improper generic drug substitution that is the subject of the federal purported class action lawsuits. The complaints seek, among other things, damages, restitution and injunctive relief. The Isak and Fragnoli actions were later consolidated by agreement of the parties. On January 12, 2007, the defendants filed a motion to dismiss the consolidated action on the grounds that the dismissal of the substantially identical shareholder derivative action, Irwinv. Gemunder, et al., 2:06cv62, by the United States District Court for the Eastern District of Kentucky on November 20, 2006 should be given preclusive effect and thus bars re-litigation of the issues already decided in Irwin. Instead of opposing that motion, on March 16, 2007, the plaintiffs filed an amended consolidated complaint, which continues to name all of the directors as defendants and asserts the same claims, but attempts to bolster those claims by adding nearly all of the substantive allegations from the most recent complaint in the federal securities class action (see discussion of HOD Carriers above) and an amended complaint in Irwin that added the same factual allegations that were added to the consolidated amended complaint in the HOD Carriers action. On April 16, 2007, defendants filed a supplemental memorandum of law in further support of their pending motion to dismiss contending that the amended complaint should be dismissed on the same grounds previously articulated for dismissal, namely, the preclusive effect of the dismissal of the Irwin action. That motion has been fully briefed, oral argument was held on August 21, 2007, and the court reserved decision.

The Company believes the above-described purported class and derivative actions are without merit and will be vigorously defended.

Although the Company cannot predict the ultimate outcome of the matters described in the preceding paragraphs, there can be no assurance that the resolution of these matters will not have a material adverse impact on the Company’s consolidated results of operations, financial position or cash flows.

As part of its ongoing operations, the Company is subject to various inspections, audits, inquiries and similar actions by governmental/regulatory authorities responsible for enforcing laws and regulations to which the Company is subject, including reviews of individual Omnicare pharmacy's reimbursement documentation and administrative practices.

61

ITEM 1A - RISK FACTORS

The Omnicare 2007 Annual Report on Form 10-K includes a detailed discussion of our risk factors. The information presented below updates and should be read in conjunction with the risk factors and information disclosed in that Form 10-K.

Risks Relating to Our Business

Federal and state healthcare legislation has significantly impacted our business, and future legislation and regulations are likely to affect us.

In recent years, federal legislation has resulted in major changes in the healthcare system, which significantly affected healthcare providers. The Balanced Budget Act of 1997 (the “BBA”) mandated a prospective payment system (“PPS”) for Medicare-eligible residents of skilled nursing facilities (“SNFs”). Under PPS, Medicare pays SNFs a fixed fee per patient per day based upon the acuity level of the resident, covering substantially all items and services furnished during a Medicare-covered stay, including pharmacy services. PPS initially resulted in a significant reduction of reimbursement to SNFs. Congress subsequently sought to restore some of the reductions in reimbursement resulting from PPS. One provision gave SNFs a temporary rate increase for certain specific high-acuity patients beginning April 1, 2000, and ending when the Centers for Medicare & Medicaid Services (“CMS”) implemented a refined patient classification system under PPS. For several years, CMS did not implement such refinements, thus continuing the additional rate increase for certain high-acuity patients through federal fiscal year 2005.

On August 4, 2005, CMS issued its final SNF PPS rule for fiscal year 2006. Under the rule, CMS added nine patient classification categories to the PPS patient classification system, thus triggering the expiration of the high-acuity payments add-ons. However, CMS estimated that the rule would have a slightly positive financial impact on SNFs in fiscal year 2006 because the $1.02 billion reduction from the expiration of the add-on payments would be more than offset by a $510 million increase in the nursing case-mix weight for all of the resource utilization group categories and a $530 million increase associated with various updates to the payment rates (including updates to the wage and market basket indexes), resulting in a $20 million overall increase in payments for fiscal year 2006. The new patient classification refinements became effective on January 1, 2006, and the market basket increase became effective October 1, 2005. On July 31, 2006, CMS issued the update to the SNF PPS rates for fiscal year 2007. Effective October 1, 2006, SNFs receive the full 3.1 percent market basket increase to rates, increasing payments to SNFs by approximately $560 million for fiscal year 2007. On August 3, 2007, CMS published its final SNF PPS update for fiscal year 2008. Effective October 1, 2007, SNFs receive a 3.3 percent market basket increase, which increases Medicare payments to SNFs by approximately $690 million in fiscal year 2008. The final rule also includes several policy and payment provisions, including rebasing the market basket, which currently reflects data from fiscal 1997, to a base year of fiscal year 2004; revisions to the calculation of the SNF market basket (including revising the pharmacy component); changing the threshold for forecast error adjustments from the current 0.25 percentage point to 0.5 percentage point; and continuing a special adjustment made to cover the additional services required by nursing home residents with HIV/AIDS. On May 1, 2008, CMS released its proposed SNF PPS update for fiscal year 2009. Among other things, the proposed rule would recalibrate

62

case mix weights, resulting in an overall 3.3 percent reduction in Medicare payments. Most of the decrease would be offset by a 3.1 percent market basket increase, but if the rule were adopted as proposed, SNFs would experience a net reduction in Medicare payments of $60 million, or approximately 0.3 percent. The rule is subject to public comment until June 30, 2008, and a final rule will be issued this summer. While the fiscal year 2007 and 2008 SNF PPS rates do not decrease payments to SNFs, the potential loss of revenues associated with any proposed changes in SNF payments could, in the future, have an adverse effect on the financial condition of the Company’s SNF clients which could, in turn, adversely affect the timing or level of their payments to Omnicare.

Moreover, on February 8, 2006, the President signed into law the Deficit Reduction Act (“DRA”), which will reduce net Medicare and Medicaid spending by approximately $11 billion over five years. Among other things, the legislation reduces Medicare SNF bad debt payments by 30 percent for those individuals who are not dually eligible for Medicare and Medicaid. This provision is expected to reduce payments to SNFs by $100 million over five years (fiscal years 2006-2010). On February 4, 2008, the Bush Administration released its fiscal year 2009 budget proposal, which includes legislative and administrative proposals that would reduce Medicare spending by approximately $12.2 billion in fiscal year 2009 and $178 billion over five years. Among other things, the budget would provide no annual update for SNFs in 2009 through 2011 and a -0.65 percent adjustment to the update annually thereafter. In addition, the budget would apply a “sequester” of -0.4 percent to all Medicare provider payments when general fund contributions exceed 45 percent of program spending. The sequester order would increase each year by -0.4 percent until general revenue funding is brought back to 45 percent. The budget also would move toward site-neutral post-hospital payments to limit perceived inappropriate incentives for five conditions commonly treated in both SNFs and inpatient rehabilitation facilities. The Administration also proposes to achieve savings by issuing regulations to adjust for case mix distribution in the SNF payment system. CMS included this provision in its proposed SNF prospective payment system update for fiscal year 2009, released May 1, 2008. CMS estimates that the recalibration would result in an overall 3.3 percent reduction in Medicare payments in fiscal year 2009, although the proposed rule would partially offset the case mix recalibration payment decrease with a 3.1 percent market basket increase. In addition, the budget proposal would eliminate all bad debt reimbursements for unpaid beneficiary cost-sharing over four years. Many provisions of the proposed Bush budget would require Congressional action to implement. Separately, on August 1, 2007, the House of Representatives approved H.R. 3162, the Children’s Health and Medicare Protection Act of 2007, that included a number of Medicare policy changes, including a freeze in fiscal year 2008 SNF PPS rates at fiscal year 2007 levels. Note that while the version of the bill that ultimately passed Congress did not include Medicare provisions impacting SNF reimbursement, Congress may yet consider these and other proposals in the future that would further restrict Medicare funding for SNFs.

In December 2003, Congress enacted the Medicare Prescription Drug, Improvement and Modernization Act of 2003 (“MMA”) which included a major expansion of the Medicare prescription drug benefit under a new Medicare Part D.

Under the Medicare Part D prescription drug benefit, Medicare beneficiaries may enroll in prescription drug plans offered by private entities (or in a “fallback” plan offered on behalf of the

63

government through a contractor, to the extent private entities fail to offer a plan in a given area), which provide coverage of outpatient prescription drugs (collectively, “Part D Plans”). Part D Plans include both plans providing the drug benefit on a stand alone basis and Medicare Advantage plans providing drug coverage as a supplement to an existing medical benefit under that Medicare Advantage plan, most commonly a health maintenance organization plan. Medicare beneficiaries generally have to pay a premium to enroll in a Part D Plan, with the premium amount varying from plan to plan, although CMS provides various federal subsidies to Part D Plans to reduce the cost to beneficiaries. Effective January 1, 2006, Medicare beneficiaries who are also entitled to benefits under a state Medicaid program (so-called “dual eligibles”) have their prescription drug costs covered by the new Medicare drug benefit. Many nursing home residents Omnicare serves are dual eligibles, whose drug costs were previously covered by state Medicaid programs. In 2007, approximately 42% of Omnicare’s revenue was derived from beneficiaries covered under the federal Medicare Part D program.

CMS provides premium and cost-sharing subsidies to Part D Plans with respect to dual eligible residents of nursing homes. Such dual eligibles are not required to pay a premium for enrollment in a Part D Plan, so long as the premium for the Part D Plan in which they are enrolled is at or below the premium subsidy, nor are they required to meet deductibles or pay copayment amounts. Further, all dual eligibles who do not affirmatively enroll in a Part D Plan are automatically enrolled into a Prescription Drug Plan (“PDP”) by CMS on a random basis from among those PDPs meeting CMS criteria for low-income premiums in the PDP region. As is the case for any nursing home beneficiary, such dual eligible beneficiaries may select a different Part D Plan at any time through the Part D enrollment process. In sum, dual eligible residents of nursing homes are entitled to have their prescription drug costs covered by a Part D Plan, provided that the prescription drugs which they are taking are either on the Part D Plan’s formulary, or an exception to the plan’s formulary is granted. CMS requires the formularies of Part D Plans to include the types of drugs most commonly needed by Medicare beneficiaries and to offer an exceptions process to provide coverage for medically necessary drugs.

Pursuant to the Part D final rule, effective January 1, 2006, we obtain reimbursement for drugs we provide to enrollees of a given Part D Plan in accordance with the terms of agreements negotiated between us and that Part D Plan. We have entered into such agreements with nearly all Part D Plan sponsors under which we provide drugs and associated services to their enrollees. We continue to have ongoing discussions with Part D Plans in the ordinary course. Moreover, we may, as appropriate, renegotiate agreements. Further, the proportion of our Part D business serviced under specific agreements may change over time. Consequently, there can be no assurance that the reimbursement terms which currently apply to our Part D business will not change. Moreover, as expected in the transition to a new program of this magnitude, certain administrative and payment issues have arisen, resulting in higher operating expenses, as well as outstanding gross accounts receivable (net of allowances for contractual adjustments, and prior to any allowance for doubtful accounts) for copays and rejected claims. As of March 31, 2008, copays outstanding from Part D Plans were approximately $43 million, of which approximately $19 million relates to 2006. Additionally, as of March 31, 2008, Part D rejected claims outstanding from Part D Plans for the 2006 transitional year were approximately $21 million. Participants in the long-term care pharmacy industry continue to address these issues with CMS and the Part D Plans and attempt to develop solutions. The Company is also pursuing legal

64

actions against certain Part D payors to collect outstanding copays. However, until all administrative and payment issues are fully resolved, there can be no assurance that the impact of the Part D Drug benefit on our results of operations, financial position or cash flows will not change based on the outcome of any unforeseen future developments.

The MMA does not change the manner in which Medicare pays for drugs for Medicare beneficiaries covered under a Medicare Part A stay. We continue to receive reimbursement for drugs provided to such residents from the SNFs, in accordance with the terms of the agreements we have negotiated with each SNF. We also continue to receive reimbursement from the state Medicaid programs, albeit to a greatly reduced extent, for those Medicaid beneficiaries not eligible for the Part D program, including those under age 65, and for certain drugs specifically excluded from Medicare Part D.

CMS has issued subregulatory guidance on many aspects of the final Part D rule, including the provision of pharmaceutical services to long-term care residents. CMS has also expressed some concerns about pharmacies’ receipt of discounts, rebates and other price concessions from drug manufacturers. Specifically, in a finalized “Call Letter” for the 2007 calendar year, CMS indicated that beginning in 2007, Part D sponsors must have policies and systems in place, as part of their drug utilization management programs, to protect beneficiaries and reduce costs when long-term care pharmacies are subject to incentives to move market share through access/performance rebates from drug manufacturers. For the purposes of managing and monitoring drug utilization, especially where such rebates exist, CMS instructs Part D Plan sponsors to require pharmacies to disclose to the Part D Plan sponsor any discounts, rebates and other direct or indirect remuneration designed to directly or indirectly influence or impact utilization of Part D drugs. CMS stated that Plan sponsors should provide assurances that such information will remain confidential. CMS has issued subregulatory guidelines specifying the information that CMS is requiring from Plan sponsors with respect to rebates paid to long-term care pharmacies. CMS has also issued reporting requirements for 2008 which, among other things, require disclosure of rebates provided to long-term care pharmacies at a more detailed level. We have agreed with various Plan sponsors and their agents with respect to the format, terms and conditions for providing such information and we intend to continue to work with other sponsors with respect to providing such information.

CMS continues to issue guidance on and make revisions to the Part D program. We are continuing to monitor issues relating to implementation of the Part D benefit, and until further agency guidance is known and until all administrative and payment issues associated with the transition to this massive program are fully resolved, there can be no assurance that the impact of the final rule or the outcome of other potential developments relating to its implementation on our business, results of operations, financial position or cash flows will not change based on the outcome of any unforeseen future developments.

The MMA also changed the Medicare payment methodology and conditions for coverage of certain items of durable medical equipment prosthetics, orthotics, and supplies (“DMEPOS”) under Medicare Part B. Approximately 1% of our revenue is derived from beneficiaries covered under Medicare Part B. The changes include a temporary freeze in annual increases in payments for durable medical equipment from 2004 through 2008, new clinical conditions for payment,

65

quality standards (applied by CMS-approved accrediting organizations), and competitive bidding requirements. On April 10, 2007, CMS issued a final rule establishing the Medicare competitive bidding program. Only suppliers that are winning bidders will be eligible to provide competitively-bid items to Medicare beneficiaries in the selected areas. Enteral nutrients, equipment and supplies and oxygen equipment and supplies are among the 10 categories of DMEPOS included in the first round of the competitive bidding program for 10 geographic areas beginning July 1, 2008 (a delay from the previously-announced implementation date of April 1, 2008). We submitted bids for nine competitive bidding areas. CMS began announcing awards in March 2008. On March 20, 2008, we received form letters from Palmetto GBA, the company that CMS has contracted with as the Competitive Bidding Implementation Contractor, stating that it was unable to accept the bids due to the alleged submission of insufficient financial documentation along with its bids. However, we, in consultation with our outside advisors, believe that in fact we included the required financial documentation. As a result, CMS is reassessing our bid denials. Further, many other suppliers had bids rejected due to alleged deficiencies in their bid submissions. Industry trade reports have indicated that 63 percent of all bids in round one were rejected. On May 6, 2008, a congressional committee held a hearing due to concerns that some suppliers were improperly excluded from the bidding process. It is uncertain at this time whether our bids for the first round of competitive bidding will be accepted. In the meantime, CMS has also announced the 70 locations in which the second round of competitive bidding will be conducted later in 2008. The expanded program will apply to eight product categories, again including oxygen supplies and equipment and enteral nutrients, equipment and supplies. Bid prices will take effect sometime in 2009. Further, all existing DMEPOS suppliers will need to submit proof of accreditation by a deemed accreditation organization by September 30, 2009, although suppliers in the competitive bidding regions and new suppliers are subject to earlier accreditation deadlines. We intend to comply with all accreditation requirements for DMEPOS suppliers by the applicable deadline.

With respect to Medicaid, the BBA repealed the “Boren Amendment” federal payment standard for Medicaid payments to nursing facilities, giving states greater latitude in setting payment rates for such facilities. The law also granted states greater flexibility to establish Medicaid managed care programs without the need to obtain a federal waiver. Although these waiver programs generally exempt institutional care, including nursing facilities and institutional pharmacy services, some states do use managed care principles in their long-term care programs. Likewise, the DRA includes several changes to the Medicaid program designed to rein in program spending. These include, among others, strengthening the Medicaid asset transfer restrictions for persons seeking to qualify for Medicaid long-term care coverage, which could, due to the timing of the penalty period, increase facilities’ exposure to uncompensated care. This provision is expected to reduce Medicaid spending by an estimated $2.4 billion over five years. The law also gives states greater flexibility to expand access to home and community based services by allowing states to provide these services as an optional benefit without undergoing the waiver approval process, and includes a new demonstration to encourage states to provide long-term care services in a community setting to individuals who currently receive Medicaid services in nursing homes. Together, these provisions could increase state funding for home and community based services, while prompting states to cut funding for nursing facilities. No assurances can be given that state

66

Medicaid programs ultimately will not change the reimbursement system for long-term care or pharmacy services in a way that adversely impacts the Company.

The DRA also changed the so-called federal upper limit payment rules for multiple source prescription drugs covered under Medicaid. Like the current upper limit, it only applies to drug ingredient costs and does not include dispensing fees, which will continue to be determined by the states. First, the DRA redefined a multiple source drug subject to the upper limit rules to be a covered outpatient drug that has at least one other drug product that is therapeutically equivalent. Thus, the federal upper limit is triggered when there are two or more therapeutic equivalents, instead of three or more as was previously the case. Second, effective January 1, 2007, the DRA changed the federal upper payment limit from 150 percent of the lowest published price for a drug (which is usually the average wholesale price) to 250 percent of the lowest average manufacturer price (“AMP”). Congress expected these DRA provisions to reduce the federal and state Medicaid spending by $8.4 billion over five years. On July 17, 2007, CMS issued a final rule with comment period to implement changes to the upper limit rules. Among other things, the final rule: establishes a new federal upper limit calculation for multiple source drugs that is based on 250 percent of the lowest AMP in a drug class; promotes transparency in drug pricing by requiring CMS to post AMP amounts on its web site; and establishes a uniform definition for AMP. Additionally, the final rule provides that sales of drugs to long-term care pharmacies for supply to NHs and ALFs (as well as associated discounts, rebates or other price concessions) are not to be taken into account in determining AMP where such sales can be identified with adequate documentation, and that any AMPs which are not at least 40% of the next highest AMP will not be taken into account in determining the upper limit amount (the so-called “outlier” test). However, on December 19, 2007, the United States District Court for the District of Columbia issued a preliminary injunction that enjoins CMS from implementing provisions of the July 17, 2007 rule to the extent that it affects Medicaid reimbursement rates for retail pharmacies under the Medicaid program. The order also enjoins CMS from posting AMP data on a public website or disclosing it to states. As a result of this preliminary injunction, CMS did not post AMPs or new upper limit prices in late December 2007 based upon the July 17, 2007 final rule despite its earlier planned timetable, and the schedule for states to implement the new upper limits will be delayed until further notice. Separately, on March 14, 2008, CMS published an interim final rule with comment period revising the Medicaid rebate definition of multiple source drug set forth in the July 17, 2007 final rule. In short, the effect of the rule will be that federal upper limits apply in all states unless the state finds that a particular generic drug is not available within that state. While the rule’s effective date is April 14, 2008, it is subject to public comments and CMS also notes that the regulation is subject to the injunction by the United States District Court for the District of Columbia to the extent that it may affect Medicaid reimbursement rates for pharmacies. With the advent of Medicare Part D, our revenues from state Medicaid programs are substantially lower than has been the case previously. However, some of our agreements with Part D Plans and other payors have incorporated the Medicaid upper limit rules into the pricing mechanisms for our prescription drugs. Until the new upper limit amounts are published by CMS, we cannot predict the impact of the final rule on our business. There can be no assurance, however, that the changes under the DRA or other efforts by payors to limit reimbursement for certain drugs will not have an adverse impact on our business.

67

President Bush’s fiscal year 2009 budget proposal includes a series of proposals impacting Medicaid, including legislative and administrative changes that would reduce Medicaid payments by more than $18 billion over five years. Among other things, the proposed budget would further reduce the federal upper limit reimbursement for multiple source drugs to 150 percent of the AMP and replace the “best price” component of the Medicaid drug rebate formula with a budget-neutral flat rebate.  Many of the proposed policy changes would require Congressional approval to implement. While we have endeavored to adjust to these types of funding pressures in the past, there can be no assurance that these or future changes in Medicaid payments to nursing facilities, pharmacies, or managed care systems, or their potential impact on payments under agreements with Part D Plans, will not have an adverse impact on our business.

Two recent actions at the federal level could impact Medicaid payments to nursing facilities. The Tax Relief and Health Care Act of 2006 modified several Medicaid policies including, among other things, reducing the limit on Medicaid provider taxes from 6 percent to 5.5 percent from January 1, 2008 through September 30, 2011. The Bush Administration had been expected to issue regulations calling for deeper cuts in this funding. On February 22, 2008, CMS published a final rule that implements this legislation, and makes other clarifications to the standards for determining the permissibility of provider tax arrangements. Second, on January 18, 2007, CMS published a proposed rule designed to ensure that Medicaid payments to governmentally-operated nursing facilities and certain other health care providers are based on actual costs and that state financing arrangements are consistent with the Medicaid statute. CMS estimates that the rule, if finalized, would save $120 million during the first year and $3.87 billion over five years. On March 23, 2007, CMS published a proposed rule that would implement this legislation, and make other clarifications to the standards for determining the permissibility of provider tax arrangements. On May 29, 2007, CMS published a final rule to implement this provision, but Congress blocked the rule for one year in an emergency fiscal year 2007 spending bill, H.R. 2206. Legislation is under consideration in Congress that, if enacted, would further extend the moratorium.

Further, in order to rein in healthcare costs, we anticipate that federal and state governments will continue to review and assess alternate healthcare delivery systems, payment methodologies and operational requirements for healthcare providers, including long-term care facilities and pharmacies. Given the continuous debate regarding the cost of healthcare, managed care, universal healthcare coverage, and other healthcare issues, we cannot predict with any degree of certainty what additional healthcare initiatives, if any, will be implemented or the effect any future legislation or regulation will have on our business. Further, we receive discounts, rebates and other price concessions from pharmaceutical manufacturers pursuant to contracts for the purchase of their products. There can be no assurance that any changes in legislation or regulations, or interpretations of current law, that would eliminate or significantly reduce the discounts, rebates and other price concessions that we receive from manufacturers would not have a material adverse impact on our overall consolidated results of operations, financial position or cash flows. Longer term, funding for federal and state healthcare programs must consider the aging of the population; the growth in enrollees as eligibility is potentially expanded; the escalation in drug costs owing to higher drug utilization among seniors; the impact of the Medicare Part D benefit for seniors; the introduction of new, more efficacious but also more expensive medications; and the long-term financing of the entire Medicare program. Given competing national priorities, it remains difficult to predict the outcome and impact on us of any

68

changes in healthcare policy relating to the future funding of the Medicare and Medicaid programs. Further, Medicare, Medicaid and/or private payor rates for pharmaceutical supplies and services may not continue to be based on current methodologies or remain comparable to present levels. Any future healthcare legislation or regulation may adversely affect our business.

ITEM 2 - UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS

A summary of the Company’s repurchases of Omnicare, Inc. common stock during the quarter ended March 31, 2008 is as follows (in thousands, except per share data):

				Total Number
				of Shares
				Purchased as	Maximum Number (or
				Part of	Approximate Dollar
				Publicly	Value) of Shares that
	Total Number	Average		Announced	May Yet Be Purchased
	of Shares	Price Paid		Plans or	Under the Plans or
Period	Purchased(a)(b)	per Share		Programs	Programs(b)
January 1 - 31, 2008	0	$	-	-	$	-
February 1 - 29, 2008	56		22.66	-		-
March 1 - 31, 2008	120		17.82	-		100,000
Total	176	$	19.37	-	$	100,000

(a)

During the first quarter of 2008, the Company purchased 176 shares of Omnicare common stock in connection with its employee benefit plans, including any purchases associated with the vesting of restricted stock awards. These purchases were not made pursuant to a publicly announced repurchase plan or program.

(b)

On March 27, 2008, the Company announced that its Board of Directors has authorized a new program to repurchase, from time to time, shares of Omnicare's outstanding common stock having an aggregate value of up to $100 million, depending on market conditions and other factors. The plan does not obligate Omnicare to acquire any particular amount of common stock, and it may be modified or suspended at any time at Omnicare's discretion. During the first quarter of 2008, the Company did not purchase any shares of Omnicare common stock in connection with this program.

ITEM 6 - EXHIBITS

See Index of Exhibits.

69

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Omnicare, Inc.
	Registrant
Date: May 8, 2008	By:    /s/ David W. Froesel, Jr.
	David W. Froesel, Jr.
	Senior Vice President and
	Chief Financial Officer
	(Principal Financial and
	Accounting Officer)

INDEX OF EXHIBITS
Number and Description of Exhibit (Numbers Coincide with Item 601 of Regulation S-K)		Document Incorporated by Reference from a Previous Filing, Filed Herewith or Furnished Herewith, as Indicated Below
(3.1)	Restated Certificate of Incorporation of Omnicare, Inc. (as amended)	Form 10-K March 27, 2003
(3.3)	Second Amended and Restated By-Laws of Omnicare, Inc.	Form 10-Q November 14, 2003
(12)	Statement of Computation of Ratio of Earnings to Fixed Charges	Filed Herewith
(31.1)	Rule 13a-14(a) Certification of Chief Executive Officer of Omnicare, Inc. in accordance with Section 302 of the Sarbanes-Oxley Act of 2002	Filed Herewith
(31.2)	Rule 13a-14(a) Certification of Chief Financial Officer of Omnicare, Inc. in accordance with Section 302 of the Sarbanes-Oxley Act of 2002	Filed Herewith
(32.1)	Section 1350 Certification of Chief Executive Officer of Omnicare, Inc. in accordance with Section 906 of the Sarbanes-Oxley Act of 2002**	Furnished Herewith
(32.2)	Section 1350 Certification of Chief Financial Officer of Omnicare, Inc. in accordance with Section 906 of the Sarbanes-Oxley Act of 2002**	Furnished Herewith

** A signed original of this written statement required by Section 906 has been provided to Omnicare, Inc. and will be retained by Omnicare, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

E-1

EX-12

EXHIBIT 12
Statement of Computation of Ratio of Earnings to Fixed Charges
Omnicare, Inc. and Subsidiary Companies
(in thousands, except ratios)
Unaudited
			Three months ended
			March 31,
			2008				2007
Income before income taxes			$	49,799	(1	)	$	69,559	(1	)
Add fixed charges:
	Interest expense			35,020				40,012
	Amortization of debt expense			2,036				2,036
	Interest portion of rent expense			6,465				6,032
	Adjusted income		$	93,320			$	117,639
Fixed charges:
	Interest expense		$	35,020			$	40,012
	Amortization of debt expense			2,036				2,036
	Interest portion of rent expense			6,465				6,032
	Fixed charges		$	43,521			$	48,080
Ratio of earnings to fixed charges(2)				2.1	x			2.4	x
(1)		Income before income taxes includes the following special pretax charges:
			Three months ended
			March 31,
			2008				2007
	Restructuring and other related charges (a)		$	6,448			$	9,174
	Litigation and other related professional fees (b)			21,642				6,907
	Heartland matters (b)			1,893				5,792

	(a)		See the "Restructuring and Other Related Charges" note of the Notes to the Consolidated Financial Statements.
	(b)		See the "Commitments and Contingencies" note of the Notes to the Consolidated Financial Statements.
(2)		The ratio of earnings to fixed charges has been computed by adding income before income taxes and fixed charges to derive adjusted income, and dividing adjusted income by fixed charges. Fixed charges consist of interest expense on debt (including the amortization of debt expense) and one-third (the proportion deemed representative of the interest portion) of rent expense.

E-2

EX-31.1

Exhibit 31.1

RULE 13a-14(a) CERTIFICATION IN ACCORDANCE WITH SECTION 302 OF THE
SARBANES-OXLEY ACT OF 2002

I, Joel F. Gemunder, President and Chief Executive Officer of Omnicare, Inc. (the “Company”), certify that:

1.	I have reviewed this report on Form 10-Q of the Company;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
4.	The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:
	a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c)	evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	d)	disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and
5.	The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors:
	a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and
	b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date: May 8, 2008

/s/ Joel F. Gemunder
Joel F. Gemunder
President and Chief Executive Officer

E-3

EX-31.2

Exhibit 31.2

RULE 13a-14(a) CERTIFICATION IN ACCORDANCE WITH SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David W. Froesel, Jr., Senior Vice President and Chief Financial Officer of Omnicare, Inc. (the “Company”), certify that:

1.	I have reviewed this report on Form 10-Q of the Company;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
4.	The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:
	a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c)	evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	d)	disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and
5.	The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors:
	a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and
	b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date: May 8, 2008

/s/ David W. Froesel, Jr.
David W. Froesel, Jr.
Senior Vice President and
Chief Financial Officer

E-4

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Joel F. Gemunder, President and Chief Executive Officer of Omnicare, Inc. (the “Company”), do hereby certify in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.	The Quarterly Report on Form 10-Q of the Company for the period ended March 31, 2008 (the “Periodic Report”) fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
2.	The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 8, 2008

/s/ Joel F. Gemunder
Joel F. Gemunder
President and Chief Executive Officer

E-5

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, David W. Froesel, Jr., Senior Vice President and Chief Financial Officer of Omnicare, Inc. (the “Company”), do hereby certify in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.	The Quarterly Report on Form 10-Q of the Company for the period ended March 31, 2008 (the “Periodic Report”) fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
2.	The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 8, 2008

/s/ David W. Froesel, Jr.
David W. Froesel, Jr.
Senior Vice President and
Chief Financial Officer

E-6